lansoprazole has been researched along with Helicobacter Infections in 662 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study (April 5, 2017, to July 19, 2019), patients with ≥ 1 endoscopically confirmed duodenal ulcer, at 52 hospitals (China, South Korea, and Taiwan), received vonoprazan 20 mg once daily (QD) or lansoprazole 30 mg QD for 6 weeks maximum." | 9.51 | Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. ( Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S, 2022) |
| "Changes in gastric histology associated with long-term maintenance therapy with lansoprazole for erosive oesophagitis have not been well described." | 9.14 | Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2010) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 9.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients." | 9.10 | Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. ( Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2002) |
| "The aim of this study was to compare the effect of a combination of lansoprazole, clarithromycin, and amoxicillin (LCA) versus placebo on the severity of symptoms in functional dyspepsia patients who were positive for Helicobacter pylori (H." | 9.10 | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. ( Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S, 2003) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 9.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 9.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 9.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "In patients who require continuous treatment with NSAIDs, lansoprazole is superior to ranitidine for healing of NSAID-associated gastric ulcers." | 9.09 | Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. ( Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 9.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 9.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "To clarify whether the depth of ulceration evaluated by endoscopic ultrasonography (EUS) influences a modified dual therapy with amoxicillin and lansoprazole for the treatment of Helicobacter pylori-positive patients with gastric ulcer." | 9.09 | Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer? ( Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H, 2000) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 9.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 9.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 9.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 9.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 9.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 9.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks." | 9.08 | Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H, 1998) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 8.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 7.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 7.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 7.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 7.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 7.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 7.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 7.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| " The optimal dosage and duration of treatment need to be specified." | 6.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 6.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "In this phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study (April 5, 2017, to July 19, 2019), patients with ≥ 1 endoscopically confirmed duodenal ulcer, at 52 hospitals (China, South Korea, and Taiwan), received vonoprazan 20 mg once daily (QD) or lansoprazole 30 mg QD for 6 weeks maximum." | 5.51 | Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. ( Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S, 2022) |
| "Body weight was measured and blood was collected before and 12 weeks after H." | 5.43 | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. ( Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J, 2016) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 5.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 5.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "Helicobacter pylori causes chronic gastritis, gastroduodenal ulcers, and gastric cancer, and has been treated with two antibiotics (amoxicillin and clarithromycin) and proton-pump inhibitors (PPIs)." | 5.22 | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. ( Chun, J; Kim, BG; Kim, BS; Kim, JS; Kim, JW; Koh, SJ; Lee, KL; Oh, B, 2016) |
| " pylori infected gastritis patients were randomized to receive 7- or 14-day standard triple therapy plus bismuth with probiotic or placebo." | 5.19 | Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. ( Mahachai, V; Siramolpiwat, S; Srinarong, C; Vilaichone, RK; Wongcha-um, A, 2014) |
| "One hundred and eight patients with pangastritis were assigned to either lansoprazole 30 mg once a day (n=54) or bismuth 240 mg bis in die (n=54) for 14 days combined, for the first week, with amoxicillin 1g plus metronidazole 250 mg tris in die." | 5.14 | High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. ( Abdullahi, M; Annibale, B; Capoccia, D; Leonetti, F; Marcheggiano, A; Osborn, J; Severi, C; Tari, R; Vannella, L, 2009) |
| "Changes in gastric histology associated with long-term maintenance therapy with lansoprazole for erosive oesophagitis have not been well described." | 5.14 | Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2010) |
| "Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo." | 5.12 | Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. ( Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC, 2006) |
| "Forty-eight patients with hyperplastic gastric polyps (3-10 mm in diameter) infected with H pylori were randomly assigned to a treatment group (n = 24) which received proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole, and a control group (n = 24) which received protective agent of gastric mucosa (tepretone)." | 5.12 | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. ( Chen, JY; Ji, F; Li, YM; Ning, JW; Wang, QY; Wang, ZW, 2006) |
| " pylori-positive patients with non-ulcer dyspepsia were randomized into one of two regimens: (i) bismuth subsalicylate 300 mg q." | 5.12 | The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. ( Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A, 2007) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| " pylori positive peptic ulcer disease or functional dyspepsia were treated with two-day quadruple therapy (lansoprazole 30 mg twice daily, and colloidal bismuth subcitrate 120 mg, tetracycline 250 mg and metronidazole 250 mg, all eight times a day)." | 5.11 | The influence of pretreatment on cure rates of Helicobacter pylori eradication. ( de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 5.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| " We investigated the heartburn symptoms of patients with gastro-oesophageal reflux disease during sequential treatment with 40 mg of famotidine or 15 mg of lansoprazole to clarify whether H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| " pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b." | 5.11 | Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. ( Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z, 2004) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients." | 5.10 | Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. ( Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2002) |
| " pylori-infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b." | 5.10 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. ( Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H, 2003) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| "A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens: (i) twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg; (ii) once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg; (iii) once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg." | 5.10 | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. ( Björkman, A; Granström, M; Hoang, TT; Phung, DC; Sörberg, M; Wheeldon, TU, 2003) |
| "Eight hundred patients with functional dyspepsia were randomized to receive double-blind treatment with twice-daily 30 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days (L30AC), twice-daily 15 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days (L15AC), or once-daily 15 mg lansoprazole for 14 days (LP)." | 5.10 | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. ( Demleitner, K; Fischbach, W; Fuchs, W; Layer, P; Leodolter, A; Malfertheiner, P; MOssner, J; Stolte, M, 2003) |
| "The aim of this study was to compare the effect of a combination of lansoprazole, clarithromycin, and amoxicillin (LCA) versus placebo on the severity of symptoms in functional dyspepsia patients who were positive for Helicobacter pylori (H." | 5.10 | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. ( Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S, 2003) |
| "To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers." | 5.10 | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. ( Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM, 2003) |
| "To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication." | 5.10 | In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003) |
| "Helicobacter pylori-positive patients (224) with peptic ulcer disease or non-ulcer dyspepsia were randomized to receive one of three different omeprazole or lansoprazole-amoxycillin-clarithromycin (PPI/AC) regimens for 7 days: (1) OAC 20 regimen (n = 76), omeprazole (OPZ) 20 mg daily, amoxycillin (AMOX) 500 mg t." | 5.09 | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. ( Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S, 1999) |
| " All patients belong to a low socioeconomic strata, had multifocal atrophic gastritis documented by gastric biopsies, and had been treated previously and unsuccessfully for 2 weeks with bismuth subsalicylate (262 mg four times a day), amoxicillin (500 mg three times a day), and metronidazole (400 mg three times a day)." | 5.09 | Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. ( Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL, 1999) |
| "A health economic evaluation of triple therapy with lansoprazole, amoxicillin and clarithromycin versus 2 dual therapies (lansoprazole or omeprazole, each with amoxicillin) in the eradication of Helicobacter pylori in patients with duodenal ulcers was performed in parallel with a randomised clinical trial." | 5.09 | Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives. ( Norinder, A; Ohlin, B; Tennvall, GR, 1999) |
| "We conducted a prospective, uncontrolled study of a consecutive series of 21 peptic ulcer patients with failure of 1-week lansoprazole, amoxicillin, and clarithromycin." | 5.09 | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. ( Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA, 1999) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 5.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 5.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 5.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "In patients who require continuous treatment with NSAIDs, lansoprazole is superior to ranitidine for healing of NSAID-associated gastric ulcers." | 5.09 | Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. ( Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 5.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 5.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "To clarify whether the depth of ulceration evaluated by endoscopic ultrasonography (EUS) influences a modified dual therapy with amoxicillin and lansoprazole for the treatment of Helicobacter pylori-positive patients with gastric ulcer." | 5.09 | Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer? ( Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H, 2000) |
| " pylori who had functional dyspepsia were randomly assigned to 7 days of treatment with a lansoprazole-based triple therapy or placebo and then followed for 1 year." | 5.09 | Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. ( Chan, HH; Chen, W; Cheng, JS; Chien, EJ; Hsu, PI; Hsu, PN; Ku, MK; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Peng, NJ; Tseng, HH, 2001) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "Among the 15 patients with hemorrhagic acute gastritis who were randomly allocated to group A (eradication therapy) or group B (Lansoprazole, LPZ), 10 of them started to receive treatment within 1 day after the disease onset." | 5.09 | A short-term eradication therapy for Helicobacter pylori acute gastritis. ( Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T, 2000) |
| "Ninety patients with established peptic ulcer and NUD (with previously proven ulcer) were randomly assigned to receive either bismuth-subcitrate, amoxycillin and metrnidazole (BAM) or lansoprasole, clarithromycine and metronidazole (LCM) for 7 days." | 5.09 | The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. ( Avidan, B; Bar-Meir, S; Keller, N; Melzer, E, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "To investigate Helicobacter pylori eradication in duodenal ulcer patients with a new regimen, lansoprazole 30 mg daily for one or four weeks plus twice daily tetracycline 500 mg, clarithromycin 250 mg, and metronidazole 400 mg." | 5.09 | Quadruple therapy for symptomatic spontaneous duodenal ulcer disease. ( Bateson, MC, 2001) |
| "To compare the efficacy of one-week versus two-week treatment with lansoprazole, amoxycillin and clarithromycin in inducing healing of Helicobacter pylori-positive duodenal ulcers as well as to investigate the role of several factors, determinant in the ulcer healing process." | 5.09 | Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? ( Bianchi Porro, G; Cucino, C; Imbesi, V; Maconi, G; Russo, A, 2000) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 5.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| " pylori) infection is known to affect the gastric microcirculation, and cetraxate is reported to accelerate gastric ulcer healing, possibly by augmenting gastric mucosal blood flow (MBF)." | 5.09 | Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers. ( Adachi, K; Fujishiro, H; Ishihara, S; Kawamura, A; Kazumori, H; Kinoshita, Y; Moriyama, N; Okuyama, T; Sato, H; Suetsugu, H; Watanabe, M, 2001) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 5.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "The clinical efficacy of lansoprazole plus amoxicillin treatment in eradicating Helicobacter pylori was examined in peptic ulcer patients." | 5.08 | Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. ( Ogura, K; Ota, S; Shimada, T; Terano, A, 1995) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 5.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 5.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "We investigated the effects of omeprazole or lansoprazole on peptic ulcer healing, eradication of Helicobacter pylori (Hp) and abdominal symptoms." | 5.08 | Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer. ( Fukuda, Y; Okui, M; Shimoyama, T; Tamura, K; Yamamoto, I, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 5.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 5.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| "In an open study 66 consecutive infected patients with ulcer disease or non-ulcer dyspepsia were treated with 4-day quadruple therapy after 3 days of lansoprazole pretreatment." | 5.08 | Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. ( de Boer, WA; Schneeberger, PM; van Etten, RJ, 1998) |
| "In patients with active or a recent history of duodenal ulcer, a 14-day course of lansoprazole-based triple therapy without additional acid suppression therapy is highly effective in the eradication of H." | 5.08 | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. ( Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A, 1998) |
| "In order to explore the optimal regimens for the eradication of Helicobacter pylori (Hp), eighty-eight patients with duodenal ulcer (DU) or non-ulcer dyspepsia and Hp infection, defined by culture and histology, received the one-week triple therapy with clarithromycin (Cla), furazolidone (Fur) plus lansoprazole (Lan) or colloidal bismuth subcitrate (CBS)." | 5.08 | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. ( Liu, W; Lü, B; Xiao, S, 1996) |
| " Patients with duodenal ulcer were treated with lansoprazole alone (n = 11) or lansoprazole and amoxycillin (n = 12)." | 5.08 | Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment. ( Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E; Takashima, M, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| " pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks." | 5.08 | Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H, 1998) |
| "Sixty patients with active duodenal ulcers who tested positive for the rapid urease test had a C-14 UBT at 0 weeks (at enrollment) and at 6 and 12 weeks using 5 microCi (185 KBq) of C-14 urea." | 5.08 | Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? ( Ahuja, V; Bal, CS; Sharma, MP, 1998) |
| " pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan." | 4.82 | Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003) |
| "An 11-year-old boy with Helicobacter pylori-associated duodenal ulcer was successfully treated with a combination of lansoprazole, amoxicillin, and clarithromycin." | 4.82 | Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature. ( Iinuma, K; Kato, S; Minoura, T; Ohyauchi, M; Ozawa, K; Sekine, H; Shimosegawa, T, 2005) |
| " A daily dose of 30 mg lansoprazole reduced epigastric pain faster than omeprazole 20 mg daily in patients with peptic ulcer disease but healing rates at 4 and 8 weeks were similar with both agents at these dosages." | 4.81 | Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. ( Gremse, DA, 2001) |
| "This meta-analysis reviewed all randomized, controlled clinical trials published as full text articles in English between 1993 and 1996 that reported the efficacy of lansoprazole treatment as monotherapy or in combination with antibiotics in the treatment of peptic ulcer and in eradicating H." | 4.80 | Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. ( Bazzoli, F; Berretti, D; De Luca, L; Fossi, S; Nicolini, G; Pozzato, P; Ricciardiello, L; Zagari, M, 1998) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| " In triple therapy, two studies used the same regimen in nonulcer dyspepsia patients: lansoprazole 30 mg/day for 2 weeks, amoxicillin 2 g/day for 2 weeks, and tinidazole 1 g/day for 2 weeks." | 4.78 | Effect of lansoprazole on Helicobacter pylori. ( Lamouliatte, H, 1993) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 4.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| "In 2008, a 44-year-old woman with mild epigastralgia diagnosed as having Helicobacter pylori-positive chronic gastritis without peptic ulcer underwent eradication therapy with lansoprazole (LPZ), amoxicillin (AMPC) and clarithromycin (CAM) for 7 days, but it failed, so treatment with rabeprazole, AMPC, and metronidazole (MNZ) for another 7 days was given, but it also failed." | 3.78 | Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. ( Inoue, H; Inoue, T; Maruoka, Y; Nakajima, S, 2012) |
| " Helicobacter pylori-infected patients with gastritis and gastric ulcer received eradication therapy: lansoprazole (60 mg/day), clarithromycin (400 mg/day), and amoxicillin (1500 mg/day) for 1 week." | 3.74 | Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura. ( Arakawa, Y; Hatta, Y; Hayashi, I; Iwamoto, M; Kato, K; Kurihara, R; Kurosaka, H; Matsukawa, Y; Mizuno, S; Sawada, S, 2007) |
| "Biopsy specimens were taken from the duodenal ulcer patients who underwent gastroscopy before and after the treatment of Lansoprazole." | 3.73 | [Distribution of Helicobacter pylori in stomach before and after the administration of Lansoprazole]. ( Cheng, HY; Dong, XY; Jin, Z; Lin, SR; Ye, SM; Zhou, LY, 2005) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 3.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| " pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid." | 3.72 | Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003) |
| "This retrospective analysis evaluated data collected in a randomized, double-blind clinical trial that assessed the efficacy and safety of once-daily esomeprazole 40 mg (n = 2,624) versus lansoprazole 30 mg (n = 2,617) for up to 8 wk in the treatment of reflux-associated erosive esophagitis." | 3.72 | Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. ( Levine, D; Traxler, BM; Vakil, NB, 2004) |
| ", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting." | 3.71 | Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 3.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed." | 3.70 | Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. ( Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M, 1998) |
| "Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H." | 3.70 | Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998) |
| "We isolated strains of Helicobacter pylori from gastric mucosa of patients with peptic ulcer before and after eradication therapy, and studied their sensitivity to amoxicillin (AMPC) and clarythromycin (CAM)." | 3.70 | [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. ( Honda, T; Matsumoto, T; Mori, K; Nagatomi, Y; Takaba, M; Tsuneoka, H, 1998) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 3.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| " Given the histology and the fact that rapid urease test results were positive, chronic active gastritis with H." | 3.70 | Iron-deficiency anemia associated with Helicobacter pylori gastritis. ( Imai, T; Konno, M; Muraoka, S; Takahashi, M, 2000) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 3.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| " Sixty-six patients (with nonulcer dyspepsia, inactive ulcer, or active ulcer) were given lansoprazole (30 mg, h." | 3.69 | Endoscopic topical therapy for the treatment of Helicobacter pylori infection. ( Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y, 1996) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 3.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 3.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 3.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| " Safety was assessed by adverse event monitoring, physical examinations, vital signs, 12-lead electrocardiograms and clinical laboratory tests." | 3.11 | Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. ( Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS, 2022) |
| " Secondary outcomes included adverse events, dropout rate, and subgroup analysis." | 3.01 | Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis. ( Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL, 2023) |
| "During a median follow-up of 9." | 2.94 | Family History of Gastric Cancer and ( Choi, IJ; Joo, J; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Park, B, 2020) |
| " In contrast, patients in the SMRE group received extra short messages including dosage and time of administration twice daily." | 2.90 | Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study. ( Ji, C; Li, L; Li, Y; Liu, J; Sun, Y; Wang, T; Yang, X; Zuo, X, 2019) |
| "The most common adverse event was the dysgeusia in both the groups." | 2.87 | Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial. ( Shahbazi, S; Vahdat Shariatpanahi, Z, 2018) |
| "Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available." | 2.84 | Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the ( Arai, E; Fukui, H; Fukui, S; Kondo, T; Kono, T; Miwa, H; Ohda, Y; Okugawa, T; Oshima, T; Taki, M; Takimoto, M; Tomita, T; Tozawa, K; Watari, J; Yamasaki, T, 2017) |
| " The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28." | 2.82 | Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study. ( Benedeto-Stojanov, D; Grgov, S; Radovanović-Dinić, B; Tasić, T, 2016) |
| "Also, insulin resistance was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR)." | 2.80 | The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study. ( Dogan, Z; Ergul, B; Filik, L; Sarikaya, M, 2015) |
| "To estimate risk of H." | 2.78 | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. ( Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M, 2013) |
| " pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects." | 2.78 | Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. ( Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013) |
| "Pseudomyxoma peritonei is an understudied cancer in which an appendiceal neoplasm invades the peritoneum and forms tumor foci on abdominal organs." | 2.78 | Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. ( Dubois, A; Francis, J; Jia, Y; Liu, H; McAvoy, TJ; Merrell, DS; Nieroda, C; Sardi, A; Semino-Mora, C; Studeman, K; Testerman, TL; Whitmire, JM, 2013) |
| "pylori-positive early gastric cancer or gastric adenoma underwent endoscopic resection and were randomly allocated to eradication or placebo group in a prospective, double-blinded, and placebo-controlled manner." | 2.78 | Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial. ( Cho, WY; Choi, IJ; Jung, HC; Keum, B; Kim, JG; Kim, SG; Lee, JH; Lee, YC; Park, BJ; Park, SK; Song, HJ, 2013) |
| "Clarithromycin resistance was an important cause for eradication treatment failure." | 2.77 | Eradication of Helicobacter pylori in children in Vietnam in relation to antibiotic resistance. ( Bengtsson, C; Granström, M; Hoang, TT; Nguyen, GK; Nguyen, TV; Phung, DC; Sörberg, M; Yin, L, 2012) |
| "Ecabet sodium has an anti-H." | 2.76 | Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. ( Asaka, M; Furukawa, K; Furuta, T; Inaba, T; Ishii, N; Kamoshida, T; Kato, M; Konda, Y; Nomura, H; Sasaki, M; Shirai, T; Sugimoto, M; Tomita, T, 2011) |
| "pylori infection in causation of minimal hepatic encephalopathy (MHE) has not been well studied." | 2.76 | Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. ( Agrawal, A; Chandra, M; Gupta, A; Koowar, S, 2011) |
| "Lafutidine is a novel H(2)-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow." | 2.73 | Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. ( Chae, HS; Chang, YW; Cho, CM; Chun, HJ; Chung, IS; Hong, SJ; Jeon, WJ; Jung, HC; Kim, HU; Kim, JG; Kim, JW; Kim, N; Kim, SW; Kim, TN; Lee, GH; Lee, KJ; Lee, OJ; Lee, SW; Park, CG; Park, CH; Park, JJ; Park, JY; Park, KS; Park, MI; Park, SH; Seo, GS; Seol, S; Shim, KN; Shin, JE; Shin, WC; Shin, YW; Song, GA; Won, SY; Yoon, BC, 2008) |
| " First, optimal lansoprazole dosing schedules that would achieve sufficient acid inhibition to allow H." | 2.73 | Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. ( Furuta, T; Hishida, A; Ishizaki, T; Iwaizumi, M; Kodaira, M; Kuriyama, S; Nogaki, A; Ohashi, K; Shirai, N; Sugimoto, M; Terakawa, I; Yamade, M, 2007) |
| "The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood." | 2.73 | Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability. ( Bernasconi, G; Calafatti, SA; Deguer, M; Ecclissato, CC; Marchioretto, MA; Moraes, LA; Ortiz, RA; Pedrazzoli, J; Ribeiro, ML, 2007) |
| " Side-effect profile and tolerability were assessed using a symptom-based questionnaire." | 2.73 | Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. ( Cindoruk, M; Dursun, A; Erkan, G; Karakan, T; Unal, S, 2007) |
| "Clarithromycin resistance was indirectly assessed by the (13)C-urea breath test, with a post-treatment value cut-off point at 15." | 2.73 | Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. ( Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| "Famotidine treatment including metronidazole-amoxicillin as second-line therapy provided a high eradication rate similar to lansoprazole therapy." | 2.72 | Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. ( Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K, 2006) |
| "The absorption and bioavailability of proton pump inhibitors is influenced by food intake." | 2.72 | A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. ( Adachi, K; Azumi, T; Furuta, K; Kinoshita, Y; Koshino, K; Miki, M, 2006) |
| "pylori in family members of gastric cancer patients." | 2.71 | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. ( Bueno, ML; Castro, LP; Coelho, LG; Lopes, LG; Martins, GM; Miranda, CH; Passos, MC; Sanches, BS, 2003) |
| "Rabeprazole is a potent proton pump inhibitor that may not be affected as greatly by H." | 2.71 | Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. ( Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP, 2003) |
| "Lafutidine is a novel potent H2 receptor antagonist with gastroprotective activities such as enhancement of gastric mucosal blood flow." | 2.71 | Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. ( Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Nishiyama, H; Omagari, K; Shikuwa, S, 2003) |
| "Treatment with omeprazole or pantoprazole prior to urea breath test (UBT) was associated with low false negative results, while lansoprazole and esomeprazole caused clinically unacceptable high false negative rates (pantoprazole 2." | 2.71 | Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. ( Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H, 2004) |
| "pylori) eradication on gastroesophageal reflux disease is controversial." | 2.71 | The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004) |
| "Lansoprazole (LAN) is a proton pump inhibitor drug (PPI) metabolized by the P-450 liver cytochrome (CYP-450) system." | 2.71 | Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. ( Bellotti, M; Botta, F; Chiarbonello, B; Cotelessa, T; Emanuela, T; Fumagalli, A; Giannini, E; Malfatti, F; Milazzo, S; Podestà, E; Polegato, S; Testa, R, 2005) |
| "When lansoprazole 30 mg was given once daily, the mean 24-hour intragastric pH values in the subjects who were homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers were 4." | 2.70 | Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. ( Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Xiao, F, 2001) |
| "Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections." | 2.70 | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. ( Bartolozzi, F; Cammarota, G; Candelli, M; Cremonini, F; Di Caro, S; Gasbarrini, A; Lupascu, A; Nista, EC; Ojetti, V; Zocco, MA, 2002) |
| "A urea breath test was performed 1 month after the end of therapy; patients and investigators were blind to the results." | 2.70 | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. ( Dhir, V; Laine, L, 2002) |
| " Sixty-eight patients received 30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks (LAM group), while the other 67 patients received the same dosage of those agents plus 18,000 tyrosine units of pronase thrice daily for 2 weeks (LAMP group)." | 2.70 | Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. ( Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A, 2002) |
| "Metronidazole resistance was found in 32 of 65 (49%) patients in whom H." | 2.69 | Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance. ( Collins, BJ; Coombs, GW; Forbes, GM; McCullough, CA; Robins, PD, 1998) |
| "Miconazole is an antimycotic agent with bacteriocidal activity against Helicobacter pylori in vitro." | 2.69 | Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial. ( Ikezawa, K; Kashimura, H; Mahmudul, H; Matsuzaki, Y; Mutoh, H; Nakahara, A; Tanaka, N; Yanaka, A, 1998) |
| "All peptic ulcers were healed." | 2.69 | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. ( De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A, 1998) |
| "The 1-week triple therapy was safe and effective for eradicating H." | 2.69 | Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. ( Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T, 1998) |
| "To evaluate the efficacy of polaprezinc, a mucosal protective agent, in combination with a 7-day triple therapy containing lansoprazole, amoxycillin and clarithromycin, as a treatment for Helicobacter pylori." | 2.69 | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. ( Hassan, M; Ikezawa, K; Kashimura, H; Mutoh, H; Nakahara, A; Sawahata, T; Suzuki, K; Tanaka, N; Watanabe, T, 1999) |
| "Chronic urticaria is a common disease, though only few data on its natural course are available." | 2.69 | Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. ( Helbling, A; Pichler, WJ; Schnyder, B, 1999) |
| " Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens." | 2.69 | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. ( Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| " In this study, we focused on whether 20 mg of rabeprazole is effective in our patient population by comparing that dosage with 40 mg of rabeprazole and 60 mg of lansoprazole." | 2.69 | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. ( Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T, 2000) |
| "Patients were divided into 2 groups, one group received Lansoprazole (30 mg) once a day, and amoxycilline (500 mg) three times a day (group I), while the second group received Lansoparazole and amoxycillin in similar dosage with the addition of Roxythromycin (150 mg) twice a day (group II)." | 2.69 | Two weeks triple therapy with lansoprazole, amoxycillin and roxythromycin is better than dual therapy with lansoprazole and amoxycillin for H. pylori infection: a randomised, clinical trial. ( Alam, E; Mehdi, I; Qureshi, H, 2000) |
| " The optimal dosage and duration of treatment need to be specified." | 2.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole was found to be effective in patients who exhibited peak 13CO2 values that were at least two-thirds less than the pretreatment values." | 2.68 | 13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole. ( Kajiwara, M; Kokubun, N; Murai, S; Nakagawa, T; Ohara, H; Saito, N; Suzuki, T; Tsujino, D; Yamamoto, M; Yoneshima, M, 1995) |
| "We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies." | 2.68 | Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. ( Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 2.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "pylori infection and the ulcer recurrence rate after 1 year were investigated." | 2.68 | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| " Intragastric pH and plasma levels of the administered drugs were monitored over a dosing interval of 12 h." | 2.68 | Age-dependent eradication of Helicobacter pylori with dual therapy. ( Ammon, S; Klotz, U; Treiber, G, 1997) |
| " Possibly, 14-day therapy or a higher dosage of metronidazole provide better results with metronidazole-resistant H." | 2.68 | Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. ( el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M, 1997) |
| "Posttreatment clarithromycin resistance is common in patients who do not experience success with therapy." | 2.68 | Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. ( Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS, 1996) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| "The LCM1 regimen consisting of 30 mg lansoprazole once daily, 200 mg clarithromycin twice daily, and 250 mg metronidazole twice daily (the regular doses in ordinary use in Japan) is a highly effective and safe regimen for Japanese patients." | 2.68 | The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. ( Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Seki, M; Takimoto, T; Taniguchi, Y; Yoshida, Y, 1997) |
| "pylori associated diseases such as gastric cancer is expected." | 2.50 | [Expanded indication of National Health Insurance for H. pylori associated gastritis]. ( Kato, M, 2014) |
| " For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status." | 2.43 | Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. ( Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005) |
| "Primary thyroid MALT lymphoma occurring in Hasimoto's thyroiditis was diagnosed." | 2.42 | Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy. ( Arima, N; Tsudo, M, 2003) |
| "We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics." | 2.42 | Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. ( Beckerling, A; Gatz, G; Ulmer, HJ, 2003) |
| " Multicentre randomised controlled studies are needed to better define the efficacy profile, the optimal dosage with respect to the different indications and the safety profile for chronic therapy of proton pump inhibitors in children." | 2.42 | Proton pump inhibitors in children: a review. ( Gerarduzzi, T; Marchetti, F; Ventura, A, 2003) |
| "pylori infection and idiopathic thrombocytopenic purpura (ITP)." | 2.42 | [Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients]. ( Hirashima, N; Ito, K; Kato, A; Kato, H; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y, 2004) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | 2.41 | Motion--Helicobacter pylori worsens GERD: arguments for the motion. ( O'Morain, CA; Qasim, A, 2002) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Eradication rate of Helicobacter pylori in dual therapy (omeprazole/amoxicillin) are reported in the range of 28-91%, side effect such as loose stool and skin reaction are reported 3." | 2.40 | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. ( Iwasaki, A, 1999) |
| "When lansoprazole was used as monotherapy, the mean Hp eradication was 6% in four studies." | 2.39 | Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. ( Lamouliatte, H, 1995) |
| " Considerably more work, however, is required to identify the ideal dosage and combination that will give the best eradication rates with the simplest regimen and fewest side effects." | 2.39 | The potential value of lansoprazole in Helicobacter pylori eradication. ( Axon, AT, 1995) |
| " The bioavailability of lansoprazole is 85%; that of omeprazole is 54%." | 2.39 | Lansoprazole and omeprazole in the treatment of acid peptic disorders. ( Blum, RA, 1996) |
| "Lansoprazole, one of PPIs, is a strong antacid and it cures stomach and duodenal ulcers at early stages as well as having antibiotic action towards HP." | 2.38 | [Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy]. ( Kawano, S; Murai, M; Tamura, K; Tanaka, M, 1993) |
| "A sensitive and selective method needs to be developed and validated for simultaneous determination of four drugs (amoxacillin, tinidazole, naproxen and lansoprazole), used for treating Helicobacter pylori infection, in their combined dosage forms." | 1.72 | RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method. ( Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA, 2022) |
| "Gastric MALT lymphomas are endoscopically classified into three common types: superficial, ulcerative, and elevated types." | 1.51 | Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma. ( Chayama, K; Kitadai, Y; Masaki, S; Matsuo, K; Matsuo, T; Naito, T; Sentani, K; Takigawa, H; Tanaka, S; Urabe, Y; Yuge, R, 2019) |
| " Whether increasing the dosage of amoxicillin in a standard 7 days eradicating regimen may enhance its efficacy is not known." | 1.43 | High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. ( Franceschi, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Lopetuso, LR; Ojetti, V; Petruzziello, C; Scaldaferri, F; Tortora, A, 2016) |
| "The cumulative 5-year incidences of gastric cancer were 3." | 1.43 | Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. ( Fukayama, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shichijo, S; Ushiku, T; Yamada, A, 2016) |
| "Body weight was measured and blood was collected before and 12 weeks after H." | 1.43 | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. ( Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J, 2016) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| " We have determined a dosage regimen of lansoprazole that will provide EMs with exposure approximately equivalent to that obtained by PMs treated with standard doses and determined the exposure that a PM would experience if they were to be treated with this 'EM optimised' lansoprazole dose." | 1.37 | CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication. ( Foster, DJ; Ward, MB, 2011) |
| "Eleven patients diagnosed with MALT lymphoma were enrolled." | 1.35 | Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment. ( Asaka, M; Itoh, T; Kato, M; Kubota, K; Nakagawa, M; Ono, S; Ono, Y; Shimizu, Y, 2008) |
| "Forty-five patients with suspected gastroesophageal reflux diseases related symptoms (sore throat, throat burning, throat clearing, globus sensation, cough, halitozis, dysphonia, dysphagia, postnasal dripping, vocal fatigue, and sputum) were included in this study." | 1.35 | Association of laryngopharyngeal manifestations and gastroesophageal reflux. ( Akkaynak, C; Naiboglu, B; Ozel, L; Toros, AB; Toros, SZ; Yüksel, OD, 2009) |
| "A 53-year-old woman had demonstrated idiopathic thrombocytopenic purpura (ITP) and iron deficiency anemia (IDA) since 1978." | 1.35 | Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura. ( ASAKA, M; HASHINO, S; IMAMURA, M; KAHATA, K; KONDO, T; MORITA, R; OKADA, K; ONOZAWA, M; TAKAHATA, M, 2009) |
| "Although the possibility of preventing gastric cancer by eradicating H." | 1.35 | The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. ( Hirata, Y; Kawabe, T; Maeda, S; Mitsuno, Y; Ogura, K; Ohmae, T; Okamoto, M; Omata, M; Shibata, W; Watabe, H; Yamaji, Y; Yanai, A; Yoshida, H, 2008) |
| " On logistic regression analysis, none of the confounding factors (sex, age, indication, chronic use of PPI, eradication protocol) were found to contribute to the discrimination between a negative (successful eradication) and a positive (failed eradication) 13CUBT." | 1.33 | Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication. ( Niv, Y, 2005) |
| "In two patients with MALT lymphoma, H." | 1.33 | Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. ( Akamatsu, T; Hidaka, E; Matsuzawa, K; Okiyama, Y; Ota, H; Sano, K, 2005) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 1.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| " pylori-infected mucosa and that inhibited the loss of CAM bioavailability in the acidic environment." | 1.32 | Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. ( Fujioka, T; Kashimura, K; Kodama, M; Miura, M; Miyajima, H; Murakami, K; Nasu, M; Okimoto, T; Ootsu, S; Sato, R; Watanabe, K, 2004) |
| "Metronidazole is a good substitute for clarithromycin as the second-line option for children." | 1.32 | Results of triple eradication therapy in Japanese children: a retrospective multicenter study. ( Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N, 2004) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 1.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels." | 1.31 | Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. ( Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y, 2000) |
| "Trough steady state serum levels of lansoprazole or ranitidine, amoxycillin, clarithromycin and metronidazole were monitored in 232 patients during the last dosing interval of a 5-day quadruple H." | 1.31 | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. ( Ammon, S; Kees, F; Klotz, U; Treiber, G, 2000) |
| "pylori eradication on low-grade gastric MALT lymphoma and to investigate the whitish mucosa that appeared with regression of the lesions." | 1.31 | Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. ( Begum, S; Endo, H; Kawamata, H; Oki, Y; Sano, T; Urakami, Y, 2000) |
| "Presence of a gastroduodenal ulcer, age, gender and smoking habit did not differ significantly between the eradicated and noneradicated groups." | 1.31 | Failure of Helicobacter pylori eradication: is poor compliance the main cause? ( Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G, 2002) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| "The urea breath test was repeated at 28 days." | 1.30 | Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. ( Estrada, R; Fennerty, MB; Knigge, K; Laine, L; Trujillo, M, 1998) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 188 (28.40) | 18.2507 |
| 2000's | 348 (52.57) | 29.6817 |
| 2010's | 114 (17.22) | 24.3611 |
| 2020's | 12 (1.81) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Hassib, ST | 1 |
| Taha, EA | 1 |
| Sharf, MG | 1 |
| Mostafa, EA | 1 |
| Hou, X | 1 |
| Meng, F | 1 |
| Wang, J | 2 |
| Sha, W | 1 |
| Chiu, CT | 1 |
| Chung, WC | 1 |
| Gu, L | 1 |
| Kudou, K | 1 |
| Chong, CF | 1 |
| Zhang, S | 3 |
| Chey, WD | 8 |
| Mégraud, F | 8 |
| Laine, L | 3 |
| López, LJ | 1 |
| Hunt, BJ | 1 |
| Howden, CW | 4 |
| Gao, N | 2 |
| Yan, S | 2 |
| Chen, B | 2 |
| Kajihara, Y | 1 |
| Shimoyama, T | 14 |
| Mizuki, I | 2 |
| Zhang, WL | 1 |
| Lin, BS | 1 |
| Li, YY | 2 |
| Ding, YM | 1 |
| Han, ZX | 1 |
| Ji, R | 1 |
| Kim, BJ | 2 |
| Lee, H | 2 |
| Lee, YC | 9 |
| Jeon, SW | 3 |
| Kim, GH | 1 |
| Kim, HS | 1 |
| Sung, JK | 1 |
| Lee, DH | 2 |
| Kim, HU | 2 |
| Park, MI | 2 |
| Choi, IJ | 4 |
| Yoon, SM | 1 |
| Kim, SW | 2 |
| Baik, GH | 1 |
| Lee, JY | 7 |
| Kim, JI | 3 |
| Kim, SG | 3 |
| Kim, J | 1 |
| Lee, J | 1 |
| Kim, JG | 6 |
| Kim, JJ | 2 |
| Liou, JM | 5 |
| Chen, CC | 10 |
| Chang, CM | 1 |
| Fang, YJ | 5 |
| Bair, MJ | 4 |
| Chen, PY | 3 |
| Chang, CY | 5 |
| Hsu, YC | 4 |
| Chen, MJ | 6 |
| Yang, TH | 4 |
| Luo, JC | 5 |
| Chen, CY | 3 |
| Hsu, WF | 3 |
| Chen, YN | 2 |
| Wu, JY | 4 |
| Lin, JT | 5 |
| Lu, TP | 1 |
| Chuang, EY | 1 |
| El-Omar, EM | 3 |
| Wu, MS | 5 |
| Kikuchi, S | 3 |
| Nobeyama, Y | 1 |
| Saeki, H | 1 |
| Asahina, A | 1 |
| Nam, SY | 1 |
| Lee, SW | 4 |
| Kwon, YH | 1 |
| Lee, HS | 1 |
| Kim, CG | 1 |
| Kim, YI | 1 |
| Kook, MC | 1 |
| Park, B | 1 |
| Joo, J | 1 |
| Saxena, A | 1 |
| Mukhopadhyay, AK | 1 |
| Nandi, SP | 1 |
| Kodama, M | 10 |
| Okimoto, T | 10 |
| Mizukami, K | 1 |
| Hirashita, Y | 1 |
| Wada, Y | 1 |
| Fukuda, M | 3 |
| Matsunari, O | 1 |
| Okamoto, K | 2 |
| Ogawa, R | 1 |
| Fukuda, K | 1 |
| Kudo, Y | 1 |
| Kawahara, Y | 2 |
| Murakami, K | 13 |
| Huh, KY | 1 |
| Chung, H | 1 |
| Kim, YK | 1 |
| Lee, S | 1 |
| Bhatia, S | 1 |
| Takanami, Y | 1 |
| Nakaya, R | 1 |
| Yu, KS | 1 |
| Maruyama, M | 1 |
| Tanaka, N | 3 |
| Kubota, D | 1 |
| Miyajima, M | 1 |
| Kimura, T | 1 |
| Tokutake, K | 1 |
| Imai, R | 1 |
| Fujisawa, T | 1 |
| Mori, H | 1 |
| Matsuda, Y | 1 |
| Wada, S | 1 |
| Horiuchi, A | 1 |
| Kiyosawa, K | 3 |
| Akpinar, Z | 1 |
| Akay, S | 1 |
| Unsal, B | 1 |
| Grgov, S | 1 |
| Tasić, T | 1 |
| Radovanović-Dinić, B | 1 |
| Benedeto-Stojanov, D | 1 |
| Yagbasan, A | 1 |
| Coşkun, DÖ | 1 |
| Özbakir, Ö | 1 |
| Deniz, K | 1 |
| Gürsoy, Ş | 1 |
| Yücesoy, M | 1 |
| Auesomwang, C | 1 |
| Maneerattanaporn, M | 1 |
| Kiratisin, P | 1 |
| Leelakusolwong, S | 1 |
| Tanwandee, T | 1 |
| Robotis, J | 1 |
| Tsiodras, S | 1 |
| Rokkas, T | 1 |
| Shahbazi, S | 1 |
| Vahdat Shariatpanahi, Z | 1 |
| Liou, TC | 2 |
| Liao, PH | 1 |
| Lin, YC | 1 |
| Chu, CH | 1 |
| Shih, SC | 2 |
| Wang, T | 1 |
| Yang, X | 1 |
| Li, Y | 2 |
| Li, L | 1 |
| Liu, J | 1 |
| Ji, C | 1 |
| Sun, Y | 1 |
| Zuo, X | 1 |
| Seko, T | 1 |
| Tachi, T | 1 |
| Hatakeyama, H | 1 |
| Noguchi, Y | 1 |
| Teramachi, H | 1 |
| Takigawa, H | 1 |
| Masaki, S | 1 |
| Naito, T | 1 |
| Yuge, R | 1 |
| Urabe, Y | 1 |
| Tanaka, S | 2 |
| Sentani, K | 1 |
| Matsuo, T | 1 |
| Matsuo, K | 2 |
| Chayama, K | 2 |
| Kitadai, Y | 1 |
| Morgan, DR | 2 |
| Torres, J | 2 |
| Sexton, R | 1 |
| Herrero, R | 2 |
| Salazar-Martínez, E | 2 |
| Greenberg, ER | 2 |
| Bravo, LE | 4 |
| Dominguez, RL | 2 |
| Ferreccio, C | 2 |
| Lazcano-Ponce, EC | 2 |
| Meza-Montenegro, MM | 2 |
| Peña, EM | 2 |
| Peña, R | 2 |
| Correa, P | 4 |
| Martínez, ME | 2 |
| Valdivieso, M | 2 |
| Anderson, GL | 2 |
| Goodman, GE | 2 |
| Crowley, JJ | 2 |
| Baker, LH | 2 |
| Malfertheiner, P | 5 |
| Matsumoto, T | 4 |
| Inokuma, T | 1 |
| Imai, Y | 1 |
| Navarro-Rodriguez, T | 2 |
| Silva, FM | 3 |
| Barbuti, RC | 3 |
| Mattar, R | 2 |
| Moraes-Filho, JP | 1 |
| de Oliveira, MN | 1 |
| Bogsan, CS | 1 |
| Chinzon, D | 1 |
| Eisig, JN | 3 |
| Sierra, F | 1 |
| Forero, JD | 1 |
| Rey, M | 1 |
| Botero, ML | 1 |
| Cárdenas, A | 1 |
| Semino-Mora, C | 1 |
| Testerman, TL | 1 |
| Liu, H | 1 |
| Whitmire, JM | 1 |
| Studeman, K | 1 |
| Jia, Y | 1 |
| McAvoy, TJ | 1 |
| Francis, J | 1 |
| Nieroda, C | 1 |
| Sardi, A | 1 |
| Merrell, DS | 1 |
| Dubois, A | 1 |
| Liu, MK | 1 |
| Wu, IC | 1 |
| Lu, CY | 2 |
| Kuo, CH | 2 |
| Yu, FJ | 1 |
| Liu, CJ | 2 |
| Hsu, PI | 2 |
| Hsu, WH | 2 |
| Su, YC | 1 |
| Chen, A | 1 |
| Wu, DC | 3 |
| Kuo, FC | 3 |
| Chen, JJ | 1 |
| Asaoka, D | 3 |
| Nagahara, A | 11 |
| Matsuhisa, T | 2 |
| Takahashi, S | 9 |
| Tokunaga, K | 4 |
| Kawai, T | 4 |
| Kawakami, K | 4 |
| Suzuki, H | 10 |
| Suzuki, M | 7 |
| Nishizawa, T | 2 |
| Kurihara, N | 2 |
| Ito, M | 5 |
| Sasaki, H | 2 |
| Omata, F | 2 |
| Mizuno, S | 6 |
| Torii, A | 2 |
| Ohkusa, T | 10 |
| Mine, T | 3 |
| Sakaki, N | 3 |
| Onal, IK | 1 |
| Gokcan, H | 1 |
| Benzer, E | 1 |
| Bilir, G | 1 |
| Oztas, E | 1 |
| Ergül, B | 3 |
| Doğan, Z | 2 |
| Sarikaya, M | 2 |
| Filik, L | 3 |
| Avşar, E | 1 |
| Tiftikçi, A | 1 |
| Poturoğlu, S | 1 |
| Erzin, Y | 1 |
| Kocakaya, O | 1 |
| Dinçer, D | 1 |
| Yıldırım, B | 1 |
| Güliter, S | 3 |
| Türkay, C | 1 |
| Yılmaz, U | 2 |
| Onuk, MD | 1 |
| Bölükbaş, C | 1 |
| Ellidokuz, E | 1 |
| Bektaş, A | 1 |
| Taşan, G | 1 |
| Aytuğ, N | 1 |
| Ateş, Y | 2 |
| Kaymakoğlu, S | 1 |
| Okame, M | 1 |
| Takaya, S | 1 |
| Sato, H | 4 |
| Adachi, E | 1 |
| Ohno, N | 1 |
| Kikuchi, T | 1 |
| Koga, M | 1 |
| Oyaizu, N | 1 |
| Ota, Y | 1 |
| Fujii, T | 1 |
| Iwamoto, A | 1 |
| Koibuchi, T | 1 |
| Campanale, M | 1 |
| Nucera, E | 1 |
| Ojetti, V | 3 |
| Cesario, V | 1 |
| Di Rienzo, TA | 1 |
| D'Angelo, G | 1 |
| Pecere, S | 1 |
| Barbaro, F | 1 |
| Gigante, G | 1 |
| De Pasquale, T | 1 |
| Rizzi, A | 1 |
| Cammarota, G | 5 |
| Schiavino, D | 1 |
| Franceschi, F | 2 |
| Gasbarrini, A | 4 |
| Settin, A | 1 |
| Abdalla, AF | 1 |
| Al-Hussaini, AS | 1 |
| El-Baz, R | 1 |
| Galal, A | 1 |
| Nishida, T | 1 |
| Tsujii, M | 1 |
| Tanimura, H | 1 |
| Tsutsui, S | 1 |
| Tsuji, S | 3 |
| Takeda, A | 2 |
| Inoue, A | 1 |
| Fukui, H | 2 |
| Yoshio, T | 1 |
| Kishida, O | 1 |
| Ogawa, H | 1 |
| Oshita, M | 1 |
| Kobayashi, I | 1 |
| Zushi, S | 1 |
| Ichiba, M | 1 |
| Uenoyama, N | 1 |
| Yasunaga, Y | 1 |
| Ishihara, R | 1 |
| Yura, M | 1 |
| Komori, M | 1 |
| Egawa, S | 1 |
| Iijima, H | 1 |
| Takehara, T | 1 |
| Kato, M | 17 |
| Rakici, H | 2 |
| Akdoğan, RA | 2 |
| Bedir, R | 2 |
| Copur, A | 1 |
| Yilmaz, A | 1 |
| Heo, J | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Kim, EY | 1 |
| Lee, DW | 1 |
| Seo, HE | 1 |
| Ha, CY | 1 |
| Kim, HJ | 3 |
| Kim, ES | 1 |
| Park, KS | 2 |
| Cho, KB | 1 |
| Lee, SH | 1 |
| Jang, BI | 1 |
| Kutluk, G | 1 |
| Tutar, E | 1 |
| Bayrak, A | 1 |
| Volkan, B | 1 |
| Akyon, Y | 1 |
| Celikel, C | 1 |
| Ertem, D | 1 |
| Sakallioglu, O | 1 |
| Kim, SY | 3 |
| Park, DK | 1 |
| Kwon, KA | 2 |
| Kim, KO | 1 |
| Kim, YJ | 2 |
| Chung, JW | 2 |
| Kim, H | 1 |
| Lee, WS | 1 |
| Lee, KH | 2 |
| Bae, SH | 1 |
| Kim, MK | 1 |
| Joo, YD | 1 |
| Zang, DY | 1 |
| Jo, JC | 1 |
| Lee, SM | 3 |
| Lee, JH | 4 |
| Kim, DY | 1 |
| Ryoo, HM | 1 |
| Hyun, MS | 1 |
| Srinarong, C | 1 |
| Siramolpiwat, S | 1 |
| Wongcha-um, A | 1 |
| Mahachai, V | 4 |
| Vilaichone, RK | 2 |
| Masaoaka, T | 1 |
| Ayaz, T | 1 |
| Wu, MC | 2 |
| Huang, CY | 1 |
| Wang, SS | 2 |
| Shih, HY | 1 |
| Chen, YH | 2 |
| Huang, YL | 1 |
| Long, C | 1 |
| Cao, Z | 1 |
| Chen, Q | 3 |
| Zhang, W | 3 |
| Liang, X | 3 |
| Liao, J | 1 |
| Liu, W | 4 |
| Xiao, S | 4 |
| Lu, H | 3 |
| Tümgör, G | 1 |
| Baran, M | 1 |
| Çakır, M | 1 |
| Yüksekkaya, HA | 1 |
| Aydoğdu, S | 1 |
| Hauser, G | 1 |
| Salkic, N | 1 |
| Vukelic, K | 1 |
| JajacKnez, A | 1 |
| Stimac, D | 1 |
| Queiroz, EC | 1 |
| Iriya, K | 1 |
| Honda, M | 1 |
| Hiki, N | 2 |
| Nunobe, S | 1 |
| Ohashi, M | 1 |
| Kumagai, K | 1 |
| Hashimoto, Y | 2 |
| Mine, S | 1 |
| Kamiya, S | 3 |
| Sano, T | 4 |
| Yamaguchi, T | 2 |
| Graham, DY | 5 |
| Chang, WH | 4 |
| Tseng, CH | 4 |
| Chang, CC | 4 |
| Liu, TY | 1 |
| Hsieh, CF | 1 |
| Tsao, FY | 1 |
| Shun, CT | 4 |
| Oh, B | 1 |
| Kim, BS | 1 |
| Kim, JW | 3 |
| Kim, JS | 1 |
| Koh, SJ | 1 |
| Kim, BG | 1 |
| Lee, KL | 1 |
| Chun, J | 1 |
| Demirci, H | 1 |
| Uygun İlikhan, S | 1 |
| Öztürk, K | 1 |
| Üstündağ, Y | 1 |
| Kurt, Ö | 1 |
| Bilici, M | 1 |
| Köktürk, F | 1 |
| Uygun, A | 6 |
| Mel-Hennawi, D | 1 |
| Ahmed, MR | 2 |
| Dore, M | 1 |
| Cirks, B | 1 |
| Gleeson, T | 1 |
| Hung, HW | 1 |
| Niv, Y | 3 |
| Unler, GK | 2 |
| Ozgur, GT | 1 |
| Gokturk, HS | 2 |
| Durukan, E | 1 |
| Erhamamci, S | 1 |
| Gabrielli, M | 1 |
| Petruzziello, C | 1 |
| Tortora, A | 1 |
| Gasbarrini, G | 4 |
| Lopetuso, LR | 1 |
| Scaldaferri, F | 1 |
| Bakshi, SS | 1 |
| Sakurai, Y | 1 |
| Shiino, M | 1 |
| Funao, N | 1 |
| Nishimura, A | 1 |
| Asaka, M | 29 |
| Todo, K | 1 |
| Ohmae, T | 2 |
| Osamura, T | 1 |
| Imamura, T | 1 |
| Imashuku, S | 1 |
| Shichijo, S | 1 |
| Hirata, Y | 4 |
| Niikura, R | 1 |
| Hayakawa, Y | 1 |
| Yamada, A | 1 |
| Ushiku, T | 1 |
| Fukayama, M | 1 |
| Koike, K | 2 |
| Suzuki, S | 3 |
| Gotoda, T | 2 |
| Kusano, C | 1 |
| Iwatsuka, K | 1 |
| Moriyama, M | 1 |
| Miyaki, A | 1 |
| Yamaguchi, K | 1 |
| Ida, A | 1 |
| Miyauchi, T | 1 |
| Fu, Q | 1 |
| Kasai, C | 1 |
| Sugimoto, K | 1 |
| Moritani, I | 1 |
| Tanaka, J | 4 |
| Oya, Y | 1 |
| Inoue, H | 2 |
| Tameda, M | 1 |
| Shiraki, K | 1 |
| Takei, Y | 2 |
| Takase, K | 1 |
| Hu, WH | 4 |
| Sheu, BS | 6 |
| Takimoto, M | 1 |
| Tomita, T | 5 |
| Yamasaki, T | 1 |
| Fukui, S | 1 |
| Taki, M | 1 |
| Okugawa, T | 1 |
| Kondo, T | 3 |
| Kono, T | 1 |
| Tozawa, K | 1 |
| Arai, E | 1 |
| Ohda, Y | 1 |
| Oshima, T | 3 |
| Watari, J | 3 |
| Miwa, H | 10 |
| Ono, S | 1 |
| Ono, Y | 1 |
| Itoh, T | 3 |
| Kubota, K | 2 |
| Nakagawa, M | 4 |
| Shimizu, Y | 4 |
| Ching, SS | 1 |
| Sabanathan, S | 1 |
| Jenkinson, LR | 1 |
| Toros, SZ | 1 |
| Toros, AB | 3 |
| Yüksel, OD | 1 |
| Ozel, L | 1 |
| Akkaynak, C | 1 |
| Naiboglu, B | 1 |
| Fukase, K | 1 |
| Inoue, K | 4 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Terao, S | 1 |
| Amagai, K | 2 |
| Hayashi, S | 1 |
| Mason, JM | 1 |
| Raghunath, AS | 1 |
| Hungin, AP | 1 |
| Jackson, W | 1 |
| Isomoto, H | 4 |
| Shikuwa, S | 2 |
| Nishiyama, H | 2 |
| Kohno, S | 4 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Tsumoto, C | 1 |
| Tominaga, K | 1 |
| Okazaki, H | 1 |
| Tanigawa, T | 1 |
| Yamagami, H | 1 |
| Watanabe, K | 10 |
| Nakao, T | 1 |
| Koh, K | 1 |
| Watanabe, T | 3 |
| Fujiwara, Y | 1 |
| Yamane, T | 1 |
| Oshitani, N | 1 |
| Hino, M | 1 |
| Higuchi, K | 3 |
| Arakawa, T | 4 |
| Fagan, RP | 1 |
| Dunaway, CE | 1 |
| Bruden, DL | 1 |
| Parkinson, AJ | 2 |
| Gessner, BD | 2 |
| Zhao, F | 1 |
| Yang, Y | 1 |
| Wang, X | 1 |
| Shi, R | 1 |
| Xu, Z | 1 |
| Huang, Z | 1 |
| Zhang, G | 1 |
| Nguyen, TV | 2 |
| Bengtsson, C | 3 |
| Nguyen, GK | 2 |
| Hoang, TT | 4 |
| Phung, DC | 3 |
| Sörberg, M | 5 |
| Granström, M | 5 |
| Kim, N | 2 |
| Park, SH | 2 |
| Seo, GS | 1 |
| Lee, KJ | 2 |
| Shin, WC | 1 |
| Kim, TN | 1 |
| Park, JJ | 3 |
| Hong, SJ | 1 |
| Shim, KN | 1 |
| Shin, YW | 1 |
| Chang, YW | 1 |
| Chun, HJ | 3 |
| Lee, OJ | 1 |
| Jeon, WJ | 1 |
| Park, CG | 1 |
| Cho, CM | 1 |
| Park, CH | 1 |
| Won, SY | 1 |
| Lee, GH | 1 |
| Shin, JE | 1 |
| Park, JY | 1 |
| Chae, HS | 1 |
| Song, GA | 1 |
| Yoon, BC | 1 |
| Seol, S | 1 |
| Jung, HC | 3 |
| Chung, IS | 2 |
| Cheon, JH | 1 |
| Kim, JH | 4 |
| Lee, SK | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
| Severi, C | 2 |
| Abdullahi, M | 1 |
| Tari, R | 1 |
| Vannella, L | 2 |
| Marcheggiano, A | 2 |
| Capoccia, D | 1 |
| Leonetti, F | 1 |
| Osborn, J | 1 |
| Annibale, B | 3 |
| Pellicano, R | 1 |
| Rodriguez, TN | 1 |
| Moraes Filho, JP | 1 |
| Zaterka, S | 1 |
| Songür, Y | 1 |
| Senol, A | 1 |
| Balkarli, A | 1 |
| Baştürk, A | 1 |
| Cerçi, S | 1 |
| MORITA, R | 1 |
| HASHINO, S | 1 |
| OKADA, K | 1 |
| TAKAHATA, M | 1 |
| ONOZAWA, M | 1 |
| KAHATA, K | 1 |
| IMAMURA, M | 3 |
| Sirimontaporn, N | 2 |
| Thong-Ngam, D | 2 |
| Tumwasorn, S | 2 |
| Pontone, S | 1 |
| Standoli, M | 1 |
| Angelini, R | 1 |
| Pontone, P | 1 |
| Inoue, M | 2 |
| Okada, H | 4 |
| Hori, S | 2 |
| Kawano, S | 5 |
| Takenaka, R | 1 |
| Toyokawa, T | 1 |
| Onishi, Y | 1 |
| Shiratori, Y | 3 |
| Yamamoto, K | 2 |
| Zullo, A | 2 |
| Hassan, C | 2 |
| Cristofari, F | 1 |
| Iegri, C | 1 |
| De Francesco, V | 1 |
| Dutta, U | 1 |
| Udawat, H | 1 |
| Noor, MT | 1 |
| Sidhu, GS | 1 |
| Kochhar, R | 1 |
| Vaiphei, K | 1 |
| Singh, K | 2 |
| Haber, MM | 3 |
| Hunt, B | 1 |
| Freston, JW | 1 |
| Peura, DA | 1 |
| Kovacs, TO | 1 |
| Atkinson, S | 1 |
| Hisada, M | 1 |
| Sasaki, M | 6 |
| Ogasawara, N | 1 |
| Utsumi, K | 1 |
| Kamiya, T | 4 |
| Kataoka, H | 4 |
| Tanida, S | 4 |
| Mizoshita, T | 4 |
| Shimura, T | 3 |
| Kasugai, K | 1 |
| Joh, T | 6 |
| Erçin, CN | 1 |
| Kantarcioğlu, M | 1 |
| Kilciler, G | 1 |
| Polat, Z | 2 |
| Bağci, S | 4 |
| Ozdil, B | 1 |
| Akkiz, H | 1 |
| Bayram, S | 1 |
| Bekar, A | 1 |
| Akgöllü, E | 1 |
| Sandikçi, M | 1 |
| Mamori, S | 1 |
| Higashida, A | 1 |
| Kawara, F | 1 |
| Ohnishi, K | 1 |
| Senda, E | 1 |
| Ashida, C | 1 |
| Yamada, H | 1 |
| Matsukawa, Y | 4 |
| Iwamoto, M | 2 |
| Kato, K | 3 |
| Gon, Y | 1 |
| Hemmi, A | 1 |
| Shirinskaya, N | 1 |
| Takeuchi, J | 1 |
| Sawada, S | 2 |
| Okubo, M | 1 |
| Tahara, T | 1 |
| Shibata, T | 2 |
| Nakamura, M | 3 |
| Yoshioka, D | 1 |
| Maeda, Y | 1 |
| Yonemura, J | 1 |
| Ishizuka, T | 1 |
| Arisawa, T | 1 |
| Hirata, I | 1 |
| Ward, MB | 1 |
| Foster, DJ | 1 |
| Bekar, O | 1 |
| Yilmaz, Y | 1 |
| Gulten, M | 1 |
| Aydemir, S | 1 |
| Eren, H | 1 |
| Tekin, IO | 1 |
| Harmandar, FA | 1 |
| Demircan, N | 1 |
| Cabuk, M | 1 |
| Nadir, I | 1 |
| Yonem, O | 1 |
| Ozin, Y | 1 |
| Kilic, ZM | 1 |
| Sezgin, O | 2 |
| Taş, A | 2 |
| Akbal, E | 1 |
| Koçak, E | 2 |
| Köklü, S | 2 |
| Furuta, T | 19 |
| Sugimoto, M | 10 |
| Kamoshida, T | 2 |
| Furukawa, K | 1 |
| Inaba, T | 4 |
| Shirai, T | 3 |
| Ishii, N | 1 |
| Nomura, H | 3 |
| Konda, Y | 1 |
| Agrawal, A | 1 |
| Gupta, A | 1 |
| Chandra, M | 1 |
| Koowar, S | 1 |
| Ince, AT | 1 |
| Kesici, B | 1 |
| Saglam, M | 1 |
| Güzelbulut, F | 2 |
| Sezikli, M | 2 |
| Akkan Çetinkaya, Z | 1 |
| Erhan Altunöz, M | 1 |
| Günes, P | 1 |
| Düzgün, S | 1 |
| Ovünç Kurdas, O | 1 |
| Sato, R | 8 |
| Fujioka, T | 12 |
| Tamura, T | 4 |
| Kurata, M | 1 |
| Inoue, S | 2 |
| Goto, Y | 1 |
| Kamiya, Y | 1 |
| Kawai, S | 1 |
| Hamajima, N | 2 |
| Demir, M | 1 |
| Erbayrak, M | 1 |
| Sakalli, M | 1 |
| Jung, SW | 2 |
| Koo, JS | 2 |
| Yim, HJ | 2 |
| Choi, JH | 2 |
| Bay, A | 1 |
| Coskun, E | 1 |
| Leblebisatan, G | 1 |
| Yalcin, AS | 1 |
| Yamamoto, T | 1 |
| Takano, T | 1 |
| Higuchi, W | 1 |
| Nishiyama, A | 1 |
| Taneike, I | 1 |
| Yoshida, K | 1 |
| Kanda, H | 1 |
| Imamura, Y | 1 |
| Çetinkaya, ZA | 1 |
| Yeşil, A | 1 |
| Coşgun, S | 1 |
| Kurdaş, OÖ | 1 |
| Mazzoleni, LE | 3 |
| Francesconi, CF | 3 |
| Sander, GB | 3 |
| Tsukamoto, H | 2 |
| Mizushima, T | 3 |
| Ozeki, K | 1 |
| Nojiri, S | 1 |
| Tsukamoto, T | 3 |
| Tatematsu, M | 3 |
| Basu, PP | 1 |
| Rayapudi, K | 1 |
| Pacana, T | 1 |
| Shah, NJ | 1 |
| Krishnaswamy, N | 1 |
| Flynn, M | 1 |
| Sbrozzi-Vanni, A | 1 |
| Kanematsu, T | 1 |
| Huang, YK | 1 |
| Chang, LL | 1 |
| Wang, TH | 3 |
| Wang, WM | 1 |
| Erdur, B | 1 |
| Ozturk, Y | 1 |
| Gurbuz, ED | 1 |
| Yilmaz, O | 1 |
| Nakajima, S | 1 |
| Inoue, T | 2 |
| Maruoka, Y | 1 |
| Hyun, JJ | 1 |
| Funakoshi, R | 1 |
| Yokoyama, H | 1 |
| Kawai, N | 1 |
| Kobayashi, K | 5 |
| Ueno, F | 1 |
| Yamada, Y | 1 |
| Yin, L | 1 |
| Jung, YK | 1 |
| Lee, JJ | 1 |
| Hahm, KB | 2 |
| Jeong, JY | 1 |
| Yun, SC | 1 |
| Hsu, SJ | 1 |
| Tseng, PH | 1 |
| Wang, HP | 1 |
| Yang, UC | 1 |
| Ando, T | 2 |
| Nakajima, T | 1 |
| Inui, Y | 1 |
| Mabe, K | 1 |
| Suganuma, T | 1 |
| Satoh, K | 11 |
| Tomokane, T | 1 |
| Kudo, M | 4 |
| Take, S | 4 |
| Yamamoto, S | 1 |
| Iwamoto, J | 1 |
| Miwa, J | 1 |
| Song, HJ | 1 |
| Cho, WY | 1 |
| Keum, B | 1 |
| Park, SK | 1 |
| Park, BJ | 1 |
| Mizuno, M | 4 |
| Kawai, K | 2 |
| Yokota, K | 5 |
| Oguma, K | 3 |
| Miyoshi, M | 1 |
| Tsuji, T | 1 |
| Schilling, D | 1 |
| Adamek, HE | 1 |
| Riemann, JF | 1 |
| Sugiyama, T | 15 |
| Tsuchida, M | 1 |
| Shimodan, M | 1 |
| Kohda, K | 1 |
| Kuga, T | 1 |
| Kogawa, K | 1 |
| Kanisawa, Y | 1 |
| Kuroiwa, G | 1 |
| Hirayama, Y | 1 |
| Sato, Y | 3 |
| Niitsu, Y | 1 |
| Ushiama, H | 1 |
| Echizen, H | 1 |
| Nachi, S | 1 |
| Ohnishi, A | 1 |
| Ishibashi, S | 1 |
| Iwakiri, R | 1 |
| Shimoda, R | 1 |
| Ootani, H | 1 |
| Kawasaki, S | 1 |
| Tadano, J | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Oda, K | 1 |
| Fujise, T | 1 |
| Yoshida, T | 3 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fujimoto, K | 1 |
| Hiraishi, H | 1 |
| Ota, S | 2 |
| Terano, A | 5 |
| Boon, YH | 1 |
| Vu, C | 2 |
| Kaushik, S | 1 |
| Cheng, CS | 1 |
| Chiu, TC | 1 |
| Chian, LC | 1 |
| Mitsunaga, A | 1 |
| Matsumoto, R | 1 |
| Hoshino, Y | 2 |
| Nakamura, S | 2 |
| Murata, Y | 2 |
| Oi, I | 1 |
| Hayashi, N | 1 |
| Nakamura, T | 4 |
| Kinoshita, Y | 9 |
| Fujishiro, H | 5 |
| Amano, Y | 2 |
| Adachi, K | 8 |
| Wu, JJ | 5 |
| Lo, CY | 1 |
| Wu, HW | 1 |
| Chen, JH | 1 |
| Lin, YS | 1 |
| Lin, MD | 1 |
| Nyrén, O | 1 |
| Wong, WM | 5 |
| Wong, BC | 6 |
| Hung, WK | 1 |
| Yee, YK | 2 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Fung, FM | 2 |
| Tong, TS | 2 |
| Lai, KC | 5 |
| Yuen, MF | 2 |
| Lam, SK | 5 |
| Campbell, DR | 2 |
| Sheldon, E | 1 |
| Collis, C | 1 |
| Lukasik, N | 1 |
| Huang, B | 2 |
| Goldstein, JL | 1 |
| O'Morain, CA | 1 |
| Qasim, A | 1 |
| McColl, KE | 1 |
| Sullivan, B | 1 |
| Coyle, W | 1 |
| Nemec, R | 1 |
| Dunteman, T | 1 |
| Shirai, N | 14 |
| Watanabe, F | 1 |
| Honda, S | 1 |
| Takeuchi, K | 1 |
| Iida, T | 1 |
| Kajimura, M | 2 |
| Futami, H | 4 |
| Takayanagi, S | 1 |
| Yamada, M | 2 |
| Ohashi, K | 7 |
| Ishizaki, T | 11 |
| Hanai, H | 4 |
| Nasu, M | 6 |
| Kagawa, J | 2 |
| Sato, S | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Chuang, CH | 1 |
| Huang, AH | 3 |
| Yang, HB | 4 |
| Maiden, LP | 1 |
| Harris, AW | 5 |
| Kim, JK | 1 |
| Chung, KW | 1 |
| Sun, HS | 1 |
| Rai, R | 1 |
| Rai, S | 1 |
| Guda, N | 1 |
| Vakil, N | 1 |
| Coelho, LG | 2 |
| Martins, GM | 2 |
| Passos, MC | 2 |
| Bueno, ML | 2 |
| Sanches, BS | 1 |
| Lopes, LG | 2 |
| Miranda, CH | 1 |
| Castro, LP | 2 |
| Kawabata, H | 1 |
| Habu, Y | 1 |
| Tomioka, H | 1 |
| Kutsumi, H | 1 |
| Kobayashi, M | 1 |
| Oyasu, K | 1 |
| Hayakumo, T | 1 |
| Kiyota, K | 1 |
| Nakajima, M | 1 |
| Kimoto, K | 1 |
| Inokuchi, H | 1 |
| Mihara, T | 2 |
| Komazawa, Y | 2 |
| Miki, I | 2 |
| Aoyama, N | 5 |
| Sakai, T | 1 |
| Shirasaka, D | 4 |
| Wambura, CM | 1 |
| Maekawa, S | 3 |
| Kuroda, K | 3 |
| Kita, T | 2 |
| Sakaeda, T | 1 |
| Okumura, K | 2 |
| Kasuga, M | 3 |
| Arima, N | 1 |
| Tsudo, M | 1 |
| Urakami, Y | 3 |
| Williams, MP | 1 |
| Usselmann, B | 1 |
| Chilton, A | 1 |
| Sercombe, J | 1 |
| Nwokolo, CU | 2 |
| Pounder, RE | 1 |
| Ulmer, HJ | 1 |
| Beckerling, A | 1 |
| Gatz, G | 1 |
| Furusu, H | 1 |
| Omagari, K | 1 |
| Mizuta, Y | 2 |
| Murase, K | 1 |
| Murata, I | 1 |
| Matsuda, M | 1 |
| Noda, Y | 1 |
| Takemori, Y | 1 |
| Kuwayama, H | 4 |
| Fukuda, Y | 9 |
| Takemoto, T | 2 |
| Kimura, K | 10 |
| Shimizu, K | 2 |
| Kobayashi, S | 3 |
| Miyamoto, M | 1 |
| Haruma, K | 4 |
| Yoshihara, M | 1 |
| Sumioka, M | 1 |
| Kamada, T | 2 |
| Masuda, H | 1 |
| Nishisaka, T | 1 |
| Hammoud, F | 1 |
| El-Zimaity, HM | 4 |
| Osato, MS | 2 |
| El-Serag, HB | 1 |
| Huang, JJ | 1 |
| Ford, A | 1 |
| Moayyedi, P | 3 |
| Wheeldon, TU | 2 |
| Björkman, A | 1 |
| Lai, YC | 1 |
| Huang, SH | 1 |
| Yang, SS | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Lee, CL | 1 |
| Matsukura, N | 2 |
| Tajiri, T | 1 |
| Kato, S | 4 |
| Togashi, A | 1 |
| Masuda, G | 1 |
| Fujita, I | 1 |
| Tokunaga, A | 1 |
| Yamada, N | 1 |
| Kobayashi, Y | 1 |
| Misu, N | 1 |
| Hirako, M | 1 |
| Adachi, H | 2 |
| Nagao, T | 1 |
| Shikano, M | 1 |
| Matsuhisa, E | 1 |
| Kimura, G | 1 |
| Asaumi, N | 3 |
| Masuda, K | 1 |
| Yoshida, C | 3 |
| Kiguchi, T | 1 |
| Niiya, M | 3 |
| Niiya, K | 3 |
| Tanimoto, M | 3 |
| Uthaisaengsook, W | 1 |
| MOssner, J | 1 |
| Fischbach, W | 1 |
| Layer, P | 1 |
| Leodolter, A | 1 |
| Stolte, M | 3 |
| Demleitner, K | 1 |
| Fuchs, W | 3 |
| Vergara, M | 2 |
| Vallve, M | 2 |
| Gisbert, JP | 5 |
| Calvet, X | 2 |
| Veldhuyzen van Zanten, S | 1 |
| Fedorak, RN | 1 |
| Lambert, J | 1 |
| Cohen, L | 1 |
| Vanjaka, A | 1 |
| Lara, LF | 1 |
| Cisneros, G | 1 |
| Gurney, M | 1 |
| Van Ness, M | 1 |
| Jarjoura, D | 1 |
| Moauro, B | 1 |
| Polen, A | 1 |
| Rutecki, G | 1 |
| Whittier, F | 1 |
| Masaoka, T | 3 |
| Nomura, S | 1 |
| Kurabayashi, K | 1 |
| Minegishi, Y | 1 |
| Ishii, H | 9 |
| Chu, KM | 4 |
| Hui, WM | 3 |
| Kwok, KF | 1 |
| Hu, HC | 1 |
| Chan, OO | 1 |
| Chan, CK | 2 |
| Shibakura, M | 2 |
| Watanabe, Y | 2 |
| Kachi, M | 1 |
| Wambura, C | 2 |
| Marchetti, F | 2 |
| Gerarduzzi, T | 1 |
| Ventura, A | 1 |
| Ishiki, K | 2 |
| Nagahara, Y | 2 |
| Hamaguchi, K | 1 |
| Ogawa, K | 1 |
| Katsube, T | 1 |
| Konno, S | 1 |
| Aiba, M | 1 |
| Xiao, F | 3 |
| Rabkin, CS | 1 |
| Sugimura, H | 2 |
| Chaudhary, A | 1 |
| Ahuja, V | 4 |
| Bal, CS | 2 |
| Das, B | 2 |
| Pandey, RM | 1 |
| Sharma, MP | 6 |
| Mizuki, A | 1 |
| Tatemichi, M | 1 |
| Nishiya, H | 1 |
| Fukui, K | 1 |
| Hayashi, T | 1 |
| Tsukada, N | 1 |
| Nagata, H | 1 |
| Amarapurkar, D | 1 |
| Makesar, M | 1 |
| Amarapurkar, A | 1 |
| Das, HS | 1 |
| Bhatia, V | 1 |
| Bal, C | 2 |
| Altintas, E | 1 |
| Ulu, O | 1 |
| Aydin, O | 1 |
| Camdeviren, H | 1 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Sakabe, H | 1 |
| Yagi, Y | 1 |
| Kakinoki, R | 1 |
| Yoshikawa, K | 1 |
| Fujiyama, Y | 1 |
| Levine, A | 1 |
| Shevah, O | 1 |
| Shabat-Sehayek, V | 1 |
| Aeed, H | 1 |
| Boaz, M | 1 |
| Moss, SF | 2 |
| Avni, Y | 1 |
| Shirin, H | 1 |
| Yukselen, V | 1 |
| Yasa, MH | 1 |
| Karaoglu, AO | 1 |
| Oderda, G | 1 |
| Marinello, D | 1 |
| Lerro, P | 1 |
| Kuvidi, M | 1 |
| de'Angelis, GL | 1 |
| Ferzetti, A | 1 |
| Cucchiara, S | 1 |
| Franco, MT | 1 |
| Romano, C | 1 |
| Strisciuglio, P | 1 |
| Pensabene, L | 1 |
| Tindberg, Y | 1 |
| Casswall, TH | 1 |
| Blennow, M | 1 |
| SuzukiKurabayashi, HK | 1 |
| Kamiya, AG | 1 |
| Kondo, Y | 1 |
| Itoh, K | 1 |
| Ohara, H | 2 |
| Nomura, T | 1 |
| Itoh, M | 2 |
| Vakil, NB | 1 |
| Traxler, BM | 1 |
| Levine, D | 1 |
| Kandilci, U | 1 |
| Ebara, S | 1 |
| Schwab, M | 2 |
| Schaeffeler, E | 1 |
| Klotz, U | 5 |
| Treiber, G | 6 |
| Bago, J | 1 |
| Galović, A | 1 |
| Belosić Halle, Z | 1 |
| Bilić, A | 1 |
| Bevanda, M | 1 |
| Bago, P | 1 |
| Miyajima, H | 3 |
| Ogata, M | 1 |
| Ohtsuka, E | 1 |
| Saburi, Y | 1 |
| Janssen, MJ | 1 |
| Laheij, RJ | 1 |
| Jansen, JB | 2 |
| de Boer, WA | 9 |
| Tsutsumi, Y | 2 |
| Kanamori, H | 2 |
| Yamato, H | 2 |
| Ehira, N | 2 |
| Miura, T | 1 |
| Kawamura, T | 2 |
| Obara, S | 2 |
| Masauzi, N | 2 |
| Pilotto, A | 3 |
| Franceschi, M | 2 |
| Longoa, MG | 1 |
| Scarcelli, C | 1 |
| Orsitto, G | 1 |
| Perri, FC | 1 |
| D'Ambrosio, LP | 1 |
| Leandro, G | 3 |
| Asfeldt, AM | 1 |
| Løchen, ML | 1 |
| Straume, B | 1 |
| Steigen, SE | 1 |
| Florholmen, J | 1 |
| Goll, R | 1 |
| Nestegard, O | 1 |
| Paulssen, EJ | 1 |
| Cao, X | 1 |
| Nozaki, K | 2 |
| Shimizu, N | 2 |
| Kumagai, T | 1 |
| Kaminishi, M | 2 |
| Fukuda, S | 6 |
| Mikami, T | 2 |
| Fukushi, M | 3 |
| Munakata, A | 6 |
| Kashimura, K | 1 |
| Miura, M | 1 |
| Ootsu, S | 1 |
| Konno, M | 3 |
| Maisawa, S | 1 |
| Tajiri, H | 1 |
| Yoshimura, N | 1 |
| Shimizu, T | 5 |
| Toyoda, S | 1 |
| Nakayama, Y | 1 |
| Iinuma, K | 3 |
| Kato, A | 1 |
| Kato, H | 1 |
| Hirashima, N | 1 |
| Sakamoto, T | 1 |
| Nukaya, H | 1 |
| Ito, K | 1 |
| Matsunaga, S | 1 |
| Kondo, H | 3 |
| Tanaka, Y | 2 |
| Sakakibara, K | 1 |
| Kawabe, M | 1 |
| Kurosawa, A | 3 |
| Hojo, M | 2 |
| Iijima, K | 1 |
| Terai, T | 1 |
| Miyazaki, A | 3 |
| Sato, N | 11 |
| Hirschowitz, BI | 2 |
| Simmons, J | 2 |
| Mohnen, J | 2 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 2 |
| Sipponen, P | 2 |
| Mäkinen, J | 1 |
| Rautelin, H | 3 |
| Färkkilä, M | 1 |
| Malfatti, F | 2 |
| Giannini, E | 2 |
| Emanuela, T | 1 |
| Polegato, S | 1 |
| Podestà, E | 1 |
| Fumagalli, A | 1 |
| Cotelessa, T | 1 |
| Chiarbonello, B | 2 |
| Bellotti, M | 1 |
| Botta, F | 2 |
| Milazzo, S | 1 |
| Testa, R | 2 |
| Tanaka, A | 4 |
| Imase, K | 1 |
| Sugano, H | 1 |
| Kai, A | 1 |
| Ishida, H | 3 |
| Ozawa, K | 1 |
| Sekine, H | 1 |
| Ohyauchi, M | 1 |
| Shimosegawa, T | 2 |
| Minoura, T | 1 |
| Mana, F | 1 |
| Van Laer, W | 1 |
| Van Laere, W | 1 |
| Bossuyt, A | 1 |
| Urbain, D | 1 |
| Shintani, S | 1 |
| Hori, K | 1 |
| de Mascarel, A | 3 |
| Ruskone-Fourmestraux, A | 2 |
| Lavergne-Slove, A | 1 |
| Dubus, P | 1 |
| Merlio, JP | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lee, YJ | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Feng, LY | 1 |
| Yao, XX | 1 |
| Jiang, SL | 1 |
| Koivisto, TT | 1 |
| Rautelin, HI | 1 |
| Voutilainen, ME | 1 |
| Heikkinen, MT | 1 |
| Koskenpato, JP | 1 |
| Färkkilä, MA | 1 |
| Marusic, M | 1 |
| Babic, Z | 1 |
| Nesanovic, M | 1 |
| Lucijanic-Mlinac, M | 1 |
| Stajcar, V | 1 |
| Jin, Z | 1 |
| Dong, XY | 1 |
| Lin, SR | 2 |
| Ye, SM | 1 |
| Zhou, LY | 1 |
| Cheng, HY | 1 |
| Gedik, GK | 1 |
| Karaduman, A | 1 |
| Sivri, B | 1 |
| Caner, B | 1 |
| Ott, EA | 2 |
| Edelweiss, MI | 2 |
| Wortmann, AC | 2 |
| Theil, AL | 2 |
| Somm, G | 1 |
| Cartell, A | 2 |
| Rivero, LF | 2 |
| Uchôa, DM | 2 |
| Prolla, JC | 2 |
| Scarpignato, C | 1 |
| Takeshita, Y | 1 |
| Ueda, T | 1 |
| Imamura, K | 1 |
| Yamaguchi, H | 3 |
| Shimoyama, S | 1 |
| MaFune, K | 1 |
| Si, JM | 1 |
| Cao, Q | 1 |
| Wu, JG | 1 |
| Sagehashi, Y | 1 |
| Nakamura, A | 3 |
| Kodaira, M | 2 |
| Kenmotsu, K | 1 |
| Nagano, M | 1 |
| Egashira, T | 1 |
| Ueda, K | 1 |
| Yoneyama, M | 1 |
| Hishida, A | 5 |
| Hashimoto, T | 3 |
| Furuta, K | 2 |
| Ishihara, S | 4 |
| Hattori, S | 2 |
| Okiyama, Y | 1 |
| Matsuzawa, K | 1 |
| Hidaka, E | 1 |
| Sano, K | 1 |
| Akamatsu, T | 5 |
| Ota, H | 2 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Beinborn, M | 1 |
| Nagamatsu, S | 1 |
| Umehara, S | 1 |
| Mori, A | 1 |
| Ogura, N | 1 |
| Salih, BA | 1 |
| Abasiyanik, MF | 1 |
| Saribasak, H | 1 |
| Huten, O | 1 |
| Sander, E | 1 |
| Kim, SS | 1 |
| Meitner, P | 1 |
| Konkin, TA | 1 |
| Cho, YS | 1 |
| Resnick, MB | 1 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Natan-Eisig, J | 1 |
| Paraíso-Ferraz, JG | 1 |
| Trevisan, M | 1 |
| Zaterkaad, S | 1 |
| Chen, G | 1 |
| Takeuchi, Y | 1 |
| Kikuchi, R | 1 |
| Arai, D | 1 |
| Fukuchi, K | 1 |
| Gomi, K | 1 |
| Bruce, MG | 1 |
| Gold, BD | 2 |
| Muth, PT | 1 |
| Dunaway, E | 1 |
| Baggett, HC | 1 |
| Sakai, G | 1 |
| Hibi, T | 3 |
| Kadayifçi, A | 2 |
| Yeşilova, Z | 2 |
| Savaş, MC | 1 |
| Karslioğlu, Y | 1 |
| Ciğerim, M | 1 |
| Dağalp, K | 1 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Chan, AO | 3 |
| Wong, J | 2 |
| Giral, A | 1 |
| Celikel, CA | 1 |
| Ozdogan, O | 1 |
| Tözün, N | 2 |
| Ulusoy, NB | 1 |
| Kalayci, C | 1 |
| Krishna, M | 1 |
| Lalmuanpuii, J | 1 |
| Gurbuz, AK | 1 |
| Ozel, AM | 2 |
| Ozturk, R | 1 |
| Yildirim, S | 1 |
| Yazgan, Y | 1 |
| Demirturk, L | 1 |
| Nishiyama, M | 1 |
| Maeda, K | 1 |
| Aoyagi, K | 1 |
| Sakisaka, S | 1 |
| Koizuka, H | 1 |
| Moriyasu, F | 2 |
| Takagi, Y | 2 |
| Okudaira, K | 1 |
| Miura, S | 2 |
| Takeda, H | 9 |
| Yanaka, A | 2 |
| Fujishiro, M | 3 |
| Omata, M | 4 |
| Oka, M | 2 |
| Hiratsuka, T | 1 |
| Tamura, K | 4 |
| Hiratsuka, H | 1 |
| Suzuki, T | 3 |
| Bray, R | 1 |
| Ichinose, M | 1 |
| Nakagawa, S | 3 |
| Tsukada, K | 1 |
| Katoh, H | 1 |
| Miyazaki, T | 1 |
| Kuwano, H | 1 |
| Schaeverbeke, T | 1 |
| Broutet, N | 1 |
| Zerbib, F | 2 |
| Combe, B | 1 |
| Bertin, P | 1 |
| Lamouliatte, H | 5 |
| Perié, F | 2 |
| Joubert-Collin, M | 3 |
| Shimatani, T | 1 |
| Kuroiwa, T | 1 |
| Xu, J | 1 |
| Mieno, H | 1 |
| Tazuma, S | 1 |
| Barros, SG | 1 |
| Polanczyk, CA | 1 |
| Fritscher, LG | 1 |
| Asano, M | 1 |
| Taniwaki, H | 1 |
| Tsuji, D | 1 |
| Gu, Q | 1 |
| Agustí-Escasany, A | 1 |
| Vallano-Ferraz, A | 1 |
| Kubo, N | 1 |
| Kochi, S | 1 |
| Ariyama, I | 1 |
| Murata, M | 1 |
| Furusyo, N | 1 |
| Hayashi, J | 1 |
| Ji, F | 1 |
| Wang, ZW | 1 |
| Ning, JW | 1 |
| Wang, QY | 1 |
| Chen, JY | 1 |
| Li, YM | 1 |
| Katsuyama, T | 4 |
| Tominaga, S | 1 |
| Yoshikawa, T | 3 |
| Sakamoto, C | 1 |
| Castro Fernández, M | 1 |
| García Díaz, E | 1 |
| Larraona, JL | 1 |
| Rodríguez Hornillo, MC | 1 |
| Lamas Rojas, E | 1 |
| Núñez Hospital, D | 1 |
| Pallarés Querol, M | 1 |
| Sawaki, A | 1 |
| Wakai, K | 1 |
| Hirose, K | 1 |
| Ito, H | 1 |
| Saito, T | 1 |
| Yamao, K | 1 |
| Tajima, K | 1 |
| Zhang, L | 1 |
| Shen, L | 1 |
| Ma, JL | 1 |
| Pan, KF | 1 |
| Liu, WD | 1 |
| Li, J | 1 |
| Xiao, SD | 3 |
| Classen, M | 1 |
| You, WC | 1 |
| Padol, S | 1 |
| Yuan, Y | 1 |
| Thabane, M | 1 |
| Padol, IT | 1 |
| Hunt, RH | 2 |
| Kuzuya, T | 1 |
| Kumada, T | 1 |
| Kiriyama, S | 1 |
| Sone, Y | 1 |
| Tanikawa, M | 1 |
| Hisanaga, Y | 1 |
| Toyoda, H | 2 |
| Hayashi, K | 1 |
| Nonogaki, K | 1 |
| Shimizu, J | 1 |
| Kawase, N | 1 |
| Yamauchi, T | 1 |
| Kawachi, T | 1 |
| Ichikawa, H | 1 |
| Sayan, O | 1 |
| Akyol Erikci, A | 1 |
| Ozturk, A | 1 |
| Ang, TL | 1 |
| Fock, KM | 2 |
| Teo, EK | 1 |
| Chan, YH | 1 |
| Ng, TM | 1 |
| Chua, TS | 1 |
| Tan, JY | 1 |
| Ono, M | 1 |
| Otsu, S | 1 |
| Miki, M | 1 |
| Azumi, T | 1 |
| Koshino, K | 1 |
| Sancar, M | 1 |
| Izzettin, FV | 1 |
| Apikoglu-Rabus, S | 1 |
| Besisik, F | 1 |
| Dulger, G | 1 |
| Kast, RE | 1 |
| Myllyluoma, E | 1 |
| Ahlroos, T | 1 |
| Veijola, L | 1 |
| Tynkkynen, S | 1 |
| Korpela, R | 1 |
| Tanaka, M | 3 |
| Nakasato, F | 1 |
| Nogaki, A | 1 |
| Kuriyama, S | 1 |
| Iwaizumi, M | 1 |
| Yamade, M | 2 |
| Terakawa, I | 1 |
| Bertoli Neto, JL | 1 |
| Lourenço, LG | 1 |
| Bertoli, CF | 1 |
| Ulbrich, FS | 1 |
| Sabbi, AR | 1 |
| Bueno, AG | 1 |
| Ortiz, RA | 1 |
| Calafatti, SA | 1 |
| Moraes, LA | 1 |
| Deguer, M | 1 |
| Ecclissato, CC | 1 |
| Marchioretto, MA | 1 |
| Ribeiro, ML | 1 |
| Bernasconi, G | 1 |
| Pedrazzoli, J | 1 |
| Baldi, F | 1 |
| Hatta, Y | 1 |
| Kurihara, R | 1 |
| Arakawa, Y | 3 |
| Kurosaka, H | 2 |
| Hayashi, I | 1 |
| Itatsu, T | 1 |
| Kubota, M | 1 |
| Hayashida, Y | 1 |
| Cindoruk, M | 2 |
| Yetkin, I | 1 |
| Deger, SM | 1 |
| Karakan, T | 2 |
| Kan, E | 1 |
| Unal, S | 2 |
| Ishioka, H | 1 |
| Mikinori, K | 1 |
| Takei, K | 1 |
| Itoi, T | 1 |
| Aoki, T | 1 |
| Watanebe, K | 1 |
| Matsumoto, Y | 1 |
| Rimbara, E | 1 |
| Noguchi, N | 1 |
| Sasatsu, M | 1 |
| Yildiz, O | 1 |
| Aslan, M | 1 |
| Erdil, A | 1 |
| Gunhan, O | 1 |
| Chung, SJ | 1 |
| Jung, SH | 1 |
| Hwang, JH | 1 |
| Park, YS | 1 |
| Song, IS | 1 |
| Hagiwara, T | 1 |
| Anbo, T | 1 |
| Imamura, A | 1 |
| Suga, T | 1 |
| Uchida, T | 2 |
| Fujinaga, A | 1 |
| Yamamoto, J | 1 |
| Erkan, G | 1 |
| Dursun, A | 1 |
| Kodaira, C | 2 |
| Nishino, M | 2 |
| Ikuma, M | 2 |
| Cheng, HC | 1 |
| Chang, WL | 1 |
| Chen, WY | 1 |
| Matsushita, F | 1 |
| Nakajima, H | 1 |
| Kumagai, J | 3 |
| Senoo, K | 1 |
| Watanabe, H | 2 |
| Umemura, K | 1 |
| Richter, JA | 1 |
| Seabrook, ME | 1 |
| Shmunes, E | 1 |
| Safali, M | 1 |
| Ilgan, S | 1 |
| Wang, TE | 1 |
| Chan, YJ | 1 |
| Chen, CJ | 1 |
| Romero-Gallo, J | 1 |
| Harris, EJ | 1 |
| Krishna, U | 1 |
| Washington, MK | 1 |
| Perez-Perez, GI | 1 |
| Peek, RM | 1 |
| Ogura, K | 3 |
| Yanai, A | 1 |
| Shibata, W | 1 |
| Mitsuno, Y | 2 |
| Maeda, S | 3 |
| Watabe, H | 1 |
| Yamaji, Y | 2 |
| Okamoto, M | 2 |
| Yoshida, H | 4 |
| Kawabe, T | 2 |
| Das, KK | 1 |
| Amenta, PS | 1 |
| Tanabe, H | 2 |
| Geng, X | 1 |
| Lin, JJ | 1 |
| Kohgo, Y | 2 |
| Das, KM | 1 |
| Perez, ME | 1 |
| Youssef, NN | 1 |
| Matsui, H | 1 |
| Aikawa, C | 1 |
| Sekiya, Y | 1 |
| Murayama, SY | 1 |
| Frem, JC | 1 |
| Shehata, BM | 1 |
| Cole, CR | 1 |
| Jhala, NC | 1 |
| McFarland, MM | 1 |
| Brightman, SA | 1 |
| Morale, B | 1 |
| Rubin, W | 1 |
| Atkinson, BF | 1 |
| Shimada, T | 1 |
| Higashi, T | 1 |
| Mukuda, T | 1 |
| Imaizumi, T | 1 |
| Tatsumi, T | 1 |
| Miura, N | 1 |
| Miyajima, K | 1 |
| Noguchi, M | 1 |
| Hisano, K | 1 |
| Ochiai, T | 1 |
| Fujita, N | 2 |
| Kobayashi, T | 1 |
| Yabana, T | 1 |
| Kurokawa, I | 1 |
| Yachi, A | 1 |
| Katoh, M | 1 |
| Kudoh, M | 1 |
| Kagaya, H | 7 |
| Katagiri, M | 4 |
| Nakagawa, T | 1 |
| Yoneshima, M | 1 |
| Yamamoto, M | 1 |
| Tsujino, D | 1 |
| Murai, S | 1 |
| Saito, N | 1 |
| Kokubun, N | 1 |
| Kajiwara, M | 2 |
| Takimoto, T | 5 |
| Ido, K | 4 |
| Taniguchi, Y | 6 |
| Saifuku, K | 5 |
| Kihira, K | 6 |
| Yoshida, Y | 10 |
| Nakata, H | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Akagi, T | 1 |
| Ohkawa, K | 1 |
| Aisawa, T | 1 |
| Sakata, Y | 1 |
| Takagi, A | 2 |
| Kurumada, T | 2 |
| Ohta, U | 1 |
| Kobayashi, H | 1 |
| Harasawa, S | 2 |
| Miwa, T | 2 |
| Yamamoto, I | 2 |
| Okui, M | 2 |
| Tonokatsu, Y | 2 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Murakami, M | 4 |
| Saita, H | 4 |
| Takahashi, Y | 4 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 2 |
| Ogoshi, K | 1 |
| Kato, T | 3 |
| Sakagawa, T | 1 |
| Gummett, PA | 1 |
| Logan, RP | 1 |
| Ashworth, HM | 1 |
| Baron, JH | 2 |
| Misiewicz, JJ | 4 |
| Ponce, J | 1 |
| Nos, P | 1 |
| Cahill, RJ | 1 |
| Xia, H | 1 |
| Kilgallen, C | 1 |
| Beattie, S | 1 |
| Hamilton, H | 1 |
| O'Morain, C | 3 |
| Ozmen, MM | 1 |
| Johnson, CD | 1 |
| Choné, L | 1 |
| Fléjou, JF | 1 |
| Grignon, Y | 1 |
| Bigard, MA | 1 |
| Kohli, Y | 1 |
| Azuma, T | 3 |
| Ito, S | 3 |
| Hirai, M | 1 |
| Axon, AT | 3 |
| Florent, C | 1 |
| Arnold, R | 2 |
| Pallone, F | 2 |
| Luzza, F | 2 |
| Delle Fave, G | 1 |
| Biancone, L | 1 |
| Torsoli, A | 1 |
| Capurso, L | 1 |
| Murai, M | 1 |
| Kimura, S | 1 |
| Fukuda, T | 1 |
| Cadiot, G | 1 |
| Vissuzaine, C | 1 |
| Pospai, D | 1 |
| Ruszniewski, P | 1 |
| Potet, F | 1 |
| Mignon, M | 1 |
| Hatlebakk, JG | 2 |
| Nesje, LB | 1 |
| Hausken, T | 1 |
| Bang, CJ | 1 |
| Berstad, A | 2 |
| Schütze, K | 1 |
| Hentschel, E | 1 |
| Parente, F | 3 |
| Maconi, G | 4 |
| Bargiggia, S | 2 |
| Colombo, E | 2 |
| Bianchi Porro, G | 5 |
| Stermer, E | 1 |
| Levy, N | 1 |
| Tursi, A | 3 |
| Papa, A | 3 |
| Montalto, M | 2 |
| Fedeli, G | 2 |
| Sito, E | 1 |
| Konturek, PC | 1 |
| Bielański, W | 1 |
| Kwiecień, N | 1 |
| Konturek, SJ | 2 |
| Baniukiewicz, A | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 1 |
| Hahn, EG | 1 |
| Blum, RA | 1 |
| Jaup, BH | 1 |
| Norrby, A | 1 |
| Dickey, W | 1 |
| Kenny, BD | 1 |
| McConnell, JB | 1 |
| van Etten, RJ | 6 |
| Schade, RW | 2 |
| Ouwehand, ME | 2 |
| Schneeberger, PM | 7 |
| Tytgat, GN | 3 |
| Tokushima, H | 2 |
| Tamura, H | 2 |
| Matsumura, O | 2 |
| Murakawa, M | 2 |
| Itakura, Y | 1 |
| Itoyama, S | 2 |
| Mitarai, T | 2 |
| Isoda, K | 2 |
| Dhar, A | 3 |
| Gupta, VK | 2 |
| Srinivasan, S | 2 |
| Thor, P | 1 |
| Lorens, K | 1 |
| Tabor, S | 1 |
| Herman, R | 1 |
| Konturek, JW | 2 |
| Sukegawa, M | 4 |
| Koshiyama, T | 1 |
| Nishikawa, K | 4 |
| Hokari, K | 4 |
| Ishino, Y | 1 |
| Yamamoto, H | 2 |
| Tsujiai, T | 1 |
| Nishizono, A | 1 |
| Nagai, J | 1 |
| Tokieda, M | 1 |
| Kodama, R | 1 |
| Kubota, T | 1 |
| Boixeda, D | 2 |
| Alvarez Baleriola, I | 1 |
| Martín de Argila, C | 2 |
| Bermejo, F | 1 |
| Aller, R | 1 |
| Veneto, G | 1 |
| Cuoco, L | 1 |
| Pryce, DI | 1 |
| Gabe, SM | 1 |
| Karim, QN | 1 |
| Walker, MM | 1 |
| Langworthy, H | 5 |
| Malaty, H | 1 |
| Genta, RM | 1 |
| Cole, RA | 1 |
| Kaneko, E | 4 |
| Baba, S | 2 |
| Arai, H | 3 |
| Sekine, S | 1 |
| Hirose, H | 1 |
| Bock, H | 3 |
| Mares, A | 1 |
| Seko, A | 1 |
| Amano, K | 1 |
| Shimizu, H | 2 |
| Takagi, S | 1 |
| Goto, A | 1 |
| Sugie, S | 1 |
| Yoshimi, N | 1 |
| Moriwaki, H | 1 |
| Muto, Y | 1 |
| Wang, XM | 1 |
| Nishifuku, K | 1 |
| Kidaira, K | 1 |
| Sato, K | 7 |
| Sohara, H | 1 |
| Kawada, H | 1 |
| Caselli, M | 3 |
| Trevisani, L | 3 |
| Sartori, S | 3 |
| Ruina, M | 3 |
| Luzzi, I | 1 |
| Gaudenzi, P | 1 |
| Alvisi, V | 1 |
| Eissele, R | 1 |
| Brunner, G | 1 |
| Simon, B | 3 |
| Solcia, E | 1 |
| van Unnik, AJ | 1 |
| Woods, M | 1 |
| Scheiman, JM | 2 |
| Nostrant, TT | 1 |
| DelValle, J | 2 |
| Sumazaki, R | 1 |
| Ahmed, T | 1 |
| Matsubara, T | 1 |
| Hori, T | 1 |
| Nakahara, A | 3 |
| Takita, H | 1 |
| Hazell, SL | 2 |
| Daskalopoulous, G | 1 |
| Mitchell, HM | 2 |
| Massey, D | 1 |
| Gotoh, A | 3 |
| Kawakami, Y | 3 |
| Akahane, T | 1 |
| Müller, P | 2 |
| Lazzaroni, M | 1 |
| Nakao, K | 1 |
| Imoto, I | 1 |
| Ikemura, N | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| Lim, AG | 1 |
| Walker, C | 1 |
| Chambers, S | 1 |
| Gould, SR | 1 |
| Rattan, A | 1 |
| Kayser, S | 1 |
| Flury, R | 1 |
| Zbinden, R | 1 |
| Fried, M | 2 |
| Wirth, HP | 1 |
| Hoffman, JS | 1 |
| Hanna, G | 1 |
| Daskalopoulos, G | 1 |
| Hirakawa, T | 1 |
| Ammon, S | 3 |
| Fisher, L | 1 |
| Elta, GH | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| Hasler, WL | 1 |
| Hoffman, J | 1 |
| Graham, DP | 1 |
| Osato, M | 1 |
| Harris, A | 1 |
| Zuberi, BF | 1 |
| Lal, S | 1 |
| Sheikh, RM | 1 |
| Kuipers, EJ | 2 |
| Klinkenberg-Knol, EC | 1 |
| Festen, HP | 1 |
| Meuwissen, SG | 1 |
| Riff, DS | 1 |
| Kidd, S | 2 |
| Rose, P | 4 |
| Haber, M | 4 |
| Weissfeld, A | 4 |
| Siepman, N | 4 |
| Harford, W | 1 |
| Lanza, F | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Schwartz, H | 2 |
| Krause, R | 2 |
| Sahba, B | 2 |
| Jaup, BK | 1 |
| Shanahan, K | 1 |
| Tompkins, DS | 1 |
| Dixon, MF | 3 |
| Chalmers, DM | 1 |
| Lai, JY | 2 |
| van de Wouw, BA | 2 |
| Driessen, WM | 1 |
| Pipkin, GA | 1 |
| Dixon, JS | 1 |
| Williamson, R | 1 |
| Wood, JR | 1 |
| Matsunaga, K | 1 |
| Oofukuji, M | 1 |
| Syukuwa, S | 1 |
| Osabe, M | 1 |
| Takeno, Y | 1 |
| Shimoi, K | 2 |
| Horiuchi, T | 2 |
| Fujiki, K | 3 |
| Takashimizu, I | 3 |
| Fennerty, MB | 3 |
| Bardhan, KD | 2 |
| Levi, S | 2 |
| Cooper, BT | 2 |
| Kerr, GD | 2 |
| Piper, D | 2 |
| Berstad, AE | 1 |
| Maartmann-Moe, H | 1 |
| Brandtzaeg, P | 1 |
| Franko, TG | 1 |
| Richter, JE | 1 |
| Ohtsu, T | 1 |
| Boku, N | 1 |
| Mori, M | 3 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Kim, YS | 1 |
| Cho, SW | 1 |
| Yim, H | 1 |
| Joo, HJ | 1 |
| Verdianelli, G | 2 |
| Abbasciano, V | 2 |
| Nishinarita, S | 2 |
| Kaneko, M | 1 |
| Takei, M | 1 |
| Horie, T | 1 |
| Kawamura, F | 2 |
| Perng, CL | 1 |
| Forbes, GM | 1 |
| Collins, BJ | 1 |
| McCullough, CA | 1 |
| Coombs, GW | 1 |
| Robins, PD | 1 |
| Lindsetmo, RO | 1 |
| Johnsen, R | 1 |
| Revhaug, A | 1 |
| Meining, A | 2 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Seifert, E | 1 |
| O'Connor, HJ | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Cunnane, K | 1 |
| Scott, BB | 1 |
| Freston, J | 1 |
| Malizia, T | 1 |
| Tejada, M | 1 |
| Favini, P | 1 |
| Pizzarelli, G | 1 |
| Campa, M | 1 |
| Senesi, S | 1 |
| Yu, Z | 1 |
| Lü, B | 1 |
| Takashima, M | 3 |
| Tsuneoka, H | 1 |
| Takaba, M | 1 |
| Nagatomi, Y | 1 |
| Mori, K | 1 |
| Honda, T | 1 |
| Raymond, J | 3 |
| Kalach, N | 3 |
| Bergeret, M | 3 |
| Benhamou, PH | 3 |
| Barbet, JP | 1 |
| Gendrel, D | 2 |
| Dupont, C | 3 |
| Ikezawa, K | 2 |
| Kashimura, H | 2 |
| Mahmudul, H | 1 |
| Matsuzaki, Y | 1 |
| Mutoh, H | 2 |
| Sakaguchi, AA | 1 |
| Spinzi, GC | 1 |
| Bierti, L | 1 |
| Bortoli, A | 1 |
| Fertitta, AM | 1 |
| Lanzi, GL | 1 |
| Venturelli, R | 1 |
| Minoli, G | 1 |
| de Boer, SY | 1 |
| Siem, TH | 1 |
| Lambert, JR | 1 |
| Senouci, L | 1 |
| Coremans, A | 1 |
| Sou, Y | 2 |
| Kaitani, K | 1 |
| Nishio, K | 1 |
| Tanahashi, T | 1 |
| Kodama, T | 1 |
| Yamaoka, Y | 1 |
| Sawai, N | 1 |
| Tatsumi, Y | 1 |
| Kashima, K | 1 |
| Higashi, Y | 1 |
| Sasaki, Y | 1 |
| Kiel, G | 1 |
| Korman, MG | 1 |
| Bolin, TD | 1 |
| Nicholson, FB | 1 |
| Engelman, JL | 1 |
| Bazzoli, F | 2 |
| Pozzato, P | 2 |
| Zagari, M | 1 |
| Fossi, S | 2 |
| Ricciardiello, L | 2 |
| Nicolini, G | 2 |
| Berretti, D | 2 |
| De Luca, L | 2 |
| Cayla, R | 1 |
| Forestier, S | 1 |
| Sato, F | 1 |
| Estrada, R | 1 |
| Trujillo, M | 1 |
| Knigge, K | 1 |
| Louw, JA | 1 |
| Van Rensburg, CJ | 1 |
| Moola, S | 1 |
| Kotze, D | 1 |
| Marks, IN | 1 |
| Spadaccini, A | 1 |
| De Fanis, C | 1 |
| Sciampa, G | 1 |
| Russo, L | 1 |
| Silla, M | 1 |
| Pantaleone, U | 1 |
| Di Virgilio, M | 1 |
| Pizzicanella, G | 1 |
| Sakurazawa, T | 1 |
| Ariake, K | 1 |
| Ishii, K | 1 |
| Tanizawa, T | 2 |
| Ritsuno, H | 1 |
| Ohnuma, K | 1 |
| Peifer-Weiss, A | 1 |
| Yamagata, R | 1 |
| Yoshimura, T | 1 |
| Haga, Y | 1 |
| Suzuki, J | 1 |
| Kobayasi, I | 1 |
| Fujita, T | 1 |
| Dattilo, M | 1 |
| Figura, N | 1 |
| Kitahora, T | 2 |
| Nagahashi, S | 2 |
| Galvani, F | 1 |
| Pohle, T | 1 |
| Stoll, R | 1 |
| Kirchner, T | 1 |
| Heep, M | 2 |
| Lehn, N | 2 |
| Domschke, W | 2 |
| Iwasaki, A | 1 |
| Kouda, K | 1 |
| Watanabe, S | 3 |
| Tada, U | 1 |
| Wada, T | 1 |
| Ooishi, M | 1 |
| Yoda, Y | 1 |
| Kawamura, N | 1 |
| Ooizumi, H | 1 |
| Saitou, M | 1 |
| Kumakura, Y | 1 |
| Sugano, K | 3 |
| Kanayama, S | 1 |
| Liu, WZ | 1 |
| Shi, Y | 1 |
| Wu, SM | 1 |
| Zhang, DZ | 1 |
| Xu, WW | 1 |
| Ohkura, R | 5 |
| Murai, T | 4 |
| Suzuki, K | 3 |
| Hassan, M | 1 |
| Sawahata, T | 1 |
| Neville, PM | 1 |
| Everett, S | 1 |
| Tompkins, D | 1 |
| Mapstone, NP | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Schnyder, B | 1 |
| Helbling, A | 1 |
| Pichler, WJ | 1 |
| Bozzola, L | 1 |
| Fortunato, A | 1 |
| Rassu, M | 1 |
| Meli, S | 1 |
| Soffiati, G | 1 |
| Scagnelli, M | 1 |
| Di Mario, F | 2 |
| Valerio, G | 1 |
| Lombardo, L | 1 |
| Masoero, G | 1 |
| Della Monica, P | 1 |
| Pera, A | 1 |
| Trautmann, M | 1 |
| Riediger, C | 1 |
| Möricke, A | 1 |
| Vogt, K | 1 |
| Bohr, U | 1 |
| Glasbrenner, B | 1 |
| Hirai, S | 1 |
| Ducóns, JA | 3 |
| Santolaria, S | 2 |
| Guirao, R | 3 |
| Ferrero, M | 2 |
| Montoro, M | 3 |
| Gomollón, F | 3 |
| Sieg, A | 1 |
| Sellinger, M | 1 |
| Schlauch, D | 1 |
| Hörner, M | 1 |
| Grimley, CE | 1 |
| Penny, A | 1 |
| O'sullivan, M | 1 |
| Shebani, M | 1 |
| Lismore, JR | 1 |
| Cross, R | 1 |
| Illing, RC | 1 |
| Loft, DE | 1 |
| Mera, R | 2 |
| Realpe, JL | 2 |
| DeLany, JP | 1 |
| Sasakii, M | 1 |
| Yokoyama, Y | 1 |
| Seno, K | 1 |
| Tsuchida, K | 1 |
| Kurokawa, T | 1 |
| Campo, C | 1 |
| de Grauw, WJ | 1 |
| Melnichouk, S | 1 |
| Friendship, RM | 1 |
| Dewey, CE | 1 |
| Bildfell, R | 1 |
| Tennvall, GR | 1 |
| Norinder, A | 1 |
| Ohlin, B | 1 |
| García Cabezudo, J | 1 |
| Simón, MA | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Sammer, D | 1 |
| Lee, E | 1 |
| Spechler, SJ | 1 |
| Ishizuka, J | 1 |
| Kudo, T | 1 |
| Komatsu, Y | 3 |
| Toyota, J | 1 |
| Yoshinaga, T | 1 |
| Sekikawa, A | 1 |
| Nakazawa, T | 1 |
| Shio, S | 1 |
| Kohigashi, K | 1 |
| Saito, D | 1 |
| Ono, H | 1 |
| Oda, I | 1 |
| Hoshiya, S | 1 |
| Ninomiya, H | 1 |
| Shingaki, M | 1 |
| Saito, S | 1 |
| Van Oijen, AH | 1 |
| Hu, FL | 1 |
| Qian, SC | 1 |
| Huang, NX | 1 |
| Hu, PJ | 1 |
| Manan, C | 1 |
| Lesmana, L | 1 |
| Carpio, RE | 1 |
| Perez, JY | 1 |
| Kachintorn, U | 1 |
| Phornphutkul, K | 1 |
| Kullavanijaya, P | 2 |
| Ho, J | 1 |
| Claessens, AA | 1 |
| Heerdink, ER | 1 |
| van Eijk, JT | 1 |
| Lamers, CB | 1 |
| Leufkens, HG | 1 |
| Miyabayashi, H | 1 |
| Furihata, K | 1 |
| Ueno, I | 1 |
| van Doorn, LJ | 2 |
| Nouhan, N | 1 |
| Plaisier, AP | 1 |
| Quint, WG | 1 |
| Yamada, T | 3 |
| Ohta, K | 1 |
| Ogihara, T | 1 |
| Gomes, BS | 1 |
| Kearney, DJ | 2 |
| Brousal, A | 1 |
| Vera, J | 1 |
| Lehmann, FS | 1 |
| Drewe, J | 1 |
| Terracciano, L | 1 |
| Beglinger, C | 2 |
| Begum, S | 2 |
| Endo, H | 3 |
| Kawamata, H | 2 |
| Shashidhar, H | 1 |
| Peters, J | 1 |
| Lin, CH | 1 |
| Rabah, R | 1 |
| Thomas, R | 1 |
| Tolia, V | 1 |
| Yoshida, N | 1 |
| Kassai, K | 1 |
| Naito, Y | 1 |
| Kondo, M | 1 |
| Suto, H | 1 |
| Ito, Y | 1 |
| Miyaji, H | 1 |
| Yamazaki, Y | 2 |
| Kuriyama, M | 1 |
| Gonlachanvit, S | 1 |
| Kladchareon, N | 1 |
| Agrawal, NM | 1 |
| Safdi, MA | 1 |
| Lukasik, NL | 1 |
| Kaushik, SP | 1 |
| Kees, F | 1 |
| Bhasin, DK | 1 |
| Sharma, BC | 1 |
| Ray, P | 1 |
| Pathak, CM | 1 |
| Takahashi, M | 3 |
| Taguchi, H | 1 |
| Osaki, T | 1 |
| Hirakawa, K | 2 |
| Niigaki, M | 2 |
| Takashima, T | 1 |
| Kaji, T | 2 |
| Kawamura, A | 3 |
| Okuyama, T | 2 |
| Watanabe, M | 5 |
| van Herwaarden, MA | 1 |
| Samsom, M | 1 |
| Smout, AJ | 1 |
| Muraoka, S | 1 |
| Imai, T | 1 |
| Miwi, H | 1 |
| Ohtaka, K | 1 |
| Minowa, T | 1 |
| Cattoli, G | 1 |
| Bart, A | 1 |
| Klaver, PS | 1 |
| Robijn, RJ | 1 |
| Beumer, HJ | 1 |
| van Vugt, R | 1 |
| Pot, RG | 1 |
| van der Gaag, I | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Kusters, JG | 1 |
| Battaglia, F | 1 |
| Dal Bò, N | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Marin, R | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Ronzani, G | 1 |
| Saggioro, A | 1 |
| Tafner, G | 1 |
| Buzás György, M | 1 |
| Székely, E | 1 |
| Illyés, G | 1 |
| Széles, I | 1 |
| Weinstein, WM | 1 |
| Huang, CC | 1 |
| Lin, XZ | 1 |
| Koop, H | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Savarino, V | 1 |
| Okai, T | 1 |
| Ohtsubo, K | 1 |
| Sakai, J | 1 |
| Motoo, Y | 1 |
| Kawashima, A | 1 |
| Sawabu, N | 1 |
| Oki, Y | 1 |
| Fujiwara, T | 1 |
| Hamazaki, K | 1 |
| Ikeda, Y | 1 |
| Murashima, N | 1 |
| Akura, Y | 1 |
| Nishisita, C | 1 |
| Umekawa, Y | 1 |
| Lai, KH | 1 |
| Tseng, HH | 1 |
| Lo, GH | 1 |
| Lo, CC | 1 |
| Lin, CK | 1 |
| Cheng, JS | 1 |
| Chan, HH | 1 |
| Ku, MK | 1 |
| Peng, NJ | 1 |
| Chien, EJ | 1 |
| Chen, W | 1 |
| Hsu, PN | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Testoni, PA | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| Lanas, AI | 1 |
| Lavergne, A | 1 |
| Aegerter, PH | 1 |
| Palazzo, L | 1 |
| Molina, T | 1 |
| Rambaud, JL | 1 |
| Miyake, K | 1 |
| Kashiwagi, S | 1 |
| Shibata, N | 1 |
| Satoh, T | 1 |
| Miki, H | 1 |
| Harada, H | 1 |
| Yamanoi, Y | 1 |
| Uraoka, T | 1 |
| Sotozono, M | 1 |
| Ohmori, M | 1 |
| Sugitani, M | 1 |
| Nagata, T | 1 |
| Ishii, Y | 1 |
| Kawamura, Y | 1 |
| Komuro, S | 1 |
| Yanai, M | 1 |
| Nemoto, N | 1 |
| Russo, A | 2 |
| Vago, L | 1 |
| Imbesi, V | 3 |
| Eishi, Y | 1 |
| Yokoyama, T | 1 |
| Qureshi, H | 1 |
| Mehdi, I | 1 |
| Alam, E | 1 |
| Ohmi, N | 1 |
| Higuchi, S | 1 |
| Avidan, B | 1 |
| Melzer, E | 1 |
| Keller, N | 1 |
| Bar-Meir, S | 1 |
| Chathadi, KV | 1 |
| Montague, J | 1 |
| Ahmed, F | 1 |
| Murthy, U | 1 |
| Fischer, H | 1 |
| Huber, V | 1 |
| Boknik, P | 1 |
| Luess, H | 1 |
| Neumann, J | 1 |
| Schmitz, W | 1 |
| Bardou, M | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Fiocca, R | 1 |
| Trimboli, V | 1 |
| Schwizer, W | 1 |
| Thumshirn, M | 1 |
| Dent, J | 1 |
| Guldenschuh, I | 1 |
| Menne, D | 1 |
| Cathomas, G | 1 |
| Meyer, JM | 1 |
| Silliman, NP | 1 |
| Dixon, CA | 1 |
| Siepman, NY | 1 |
| Sugg, JE | 1 |
| Hopkins, RJ | 1 |
| Bateson, MC | 1 |
| Yamaguchi, M | 1 |
| Kimura, M | 1 |
| Mukai, K | 1 |
| Sawa, H | 1 |
| Kawamura, K | 1 |
| Shiku, H | 1 |
| Koçak, N | 1 |
| Saltik, IN | 1 |
| Ozen, H | 1 |
| Yüce, A | 1 |
| Gürakan, F | 1 |
| Ishimura, N | 1 |
| Lau, CF | 1 |
| Hui, PK | 1 |
| Fung, TT | 1 |
| Tung, SY | 1 |
| Wong, AM | 1 |
| Loo, CK | 1 |
| Lam, KM | 1 |
| Froehlich, F | 1 |
| Gonvers, JJ | 1 |
| Wietlisbach, V | 1 |
| Burnand, B | 1 |
| Hildebrand, P | 1 |
| Schneider, C | 1 |
| Saraga, E | 1 |
| Vader, JP | 1 |
| Cucino, C | 1 |
| Grigor'ev, PIa | 1 |
| Iakovenko, EP | 1 |
| Talanova, EV | 1 |
| Di Vita, G | 1 |
| Patti, R | 1 |
| Aragona, F | 1 |
| Leo, P | 1 |
| Montalto, G | 1 |
| Magaret, N | 1 |
| Burm, M | 1 |
| Faigel, D | 1 |
| Kelly, C | 1 |
| Peterson, W | 1 |
| Yang, JC | 1 |
| Yang, KC | 1 |
| Hsu, CT | 1 |
| Wang, CS | 1 |
| Kuo, CF | 1 |
| Fendrick, AM | 1 |
| Chahine, C | 1 |
| Moukhachen, O | 1 |
| Chedid, M | 1 |
| Araj, GF | 1 |
| Sharara, AI | 1 |
| Ling, KL | 1 |
| Luman, W | 1 |
| Ho, B | 1 |
| Ng, HS | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Ikeda, S | 1 |
| Tamamuro, T | 1 |
| Hamashima, C | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Mulder, CJ | 1 |
| Nusteling, K | 1 |
| Salam, I | 1 |
| Durai, D | 1 |
| Murphy, JK | 1 |
| Sundaram, B | 1 |
| Wittig, J | 1 |
| Walker, S | 1 |
| Koçkar, C | 1 |
| Oztürk, M | 1 |
| Bavbek, N | 1 |
| Gremse, DA | 1 |
| Goto, H | 1 |
| Kikuta, T | 1 |
| Ota, A | 1 |
| Tsuji, H | 1 |
| Hino, R | 1 |
| Sakurane, M | 1 |
| Shiotani, A | 1 |
| Furukawa, F | 1 |
| Barth, J | 1 |
| Hahne, W | 1 |
| Zagari, RM | 1 |
| Alampi, G | 1 |
| Di Pietro, C | 1 |
| Morelli, P | 1 |
| Roda, E | 1 |
| Miyazawa, M | 1 |
| Poon, SK | 1 |
| Chang, CS | 1 |
| Su, J | 1 |
| Lai, CH | 1 |
| Yang, CC | 1 |
| Chen, GH | 1 |
| Wang, WC | 1 |
| Kokkola, A | 1 |
| Härkönen, M | 1 |
| Haapiainen, R | 1 |
| Puolakkainen, P | 1 |
| Di Caro, S | 1 |
| Zocco, MA | 1 |
| Cremonini, F | 1 |
| Bartolozzi, F | 1 |
| Candelli, M | 1 |
| Lupascu, A | 1 |
| Nista, EC | 1 |
| Sainaghi, M | 1 |
| Sangaletti, O | 1 |
| Anderloni, A | 1 |
| Suetsugu, H | 1 |
| Moriyama, N | 1 |
| Kazumori, H | 1 |
| Gottrand, F | 1 |
| Husson, MO | 1 |
| Barbier, C | 1 |
| Odaka, T | 1 |
| Koyama, H | 1 |
| Saisho, H | 1 |
| Nomura, F | 1 |
| Bown, RL | 1 |
| Perri, F | 1 |
| Festa, V | 1 |
| Merla, A | 1 |
| Quitadamo, M | 1 |
| Clemente, R | 1 |
| Andriulli, A | 1 |
| Kusunoki, H | 1 |
| Miyatani, H | 1 |
| Tokuyama, T | 1 |
| Hirakawa, R | 1 |
| Sawada, A | 1 |
| Chiba, T | 1 |
| Kawata, H | 1 |
| Suga, M | 1 |
| Takata, H | 1 |
| Ohara, T | 1 |
| Koizumi, K | 1 |
| Kiriyama, Y | 1 |
| Wermeille, J | 1 |
| Cunningham, M | 1 |
| Dederding, JP | 1 |
| Girard, L | 1 |
| Baumann, R | 1 |
| Zelger, G | 1 |
| Buri, P | 1 |
| Metry, JM | 1 |
| Sitavanc, R | 1 |
| Gallaz, L | 1 |
| Merki, H | 1 |
| Godin, N | 1 |
| Dhir, V | 1 |
| Shimodaira, K | 1 |
| Kaneko, T | 1 |
| Ishida, K | 1 |
| Ikeno, T | 1 |
| Sugiyama, A | 1 |
| Lau, GK | 1 |
| Lai, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg[NCT04167670] | Phase 3 | 1,046 participants (Actual) | Interventional | 2019-12-10 | Completed | ||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial[NCT01906879] | Phase 4 | 1,620 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)[NCT03065868] | Phase 4 | 32 participants (Actual) | Interventional | 2015-12-09 | Completed | ||
| Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study[NCT01678027] | Phase 3 | 1,838 participants (Actual) | Interventional | 2004-11-30 | Active, not recruiting | ||
| Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients[NCT01888237] | Phase 4 | 118 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection[NCT02711176] | Phase 4 | 212 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Intraluminal Therapy for Helicobacter Pylori Infection[NCT03124420] | Phase 4 | 100 participants (Actual) | Interventional | 2017-04-28 | Completed | ||
| A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori[NCT01061437] | Phase 3 | 1,859 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Efficacy of Helicobacter Pylori Eradication for the 1st Line Treatment of Immune Thrombocytopenic Purpura (ITP) Patients With Moderate Thrombocytopenia[NCT01255332] | 26 participants (Anticipated) | Observational | 2010-09-30 | Recruiting | |||
| Helicobacter Pylori and it's Hematological Impact[NCT03629587] | 100 participants (Actual) | Observational | 2016-09-27 | Completed | |||
| Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study[NCT03177629] | Phase 3 | 54 participants (Anticipated) | Interventional | 2017-05-23 | Recruiting | ||
| High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials[NCT05863858] | Phase 3 | 162 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication[NCT02175901] | Phase 4 | 215 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial[NCT01607918] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT01537055] | Phase 4 | 600 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial[NCT04901663] | Phase 4 | 179 participants (Actual) | Interventional | 2021-06-21 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole[NCT01505127] | Phase 3 | 650 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial[NCT03208426] | Phase 4 | 240 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | ||
| Prediction for the Development of Metachronous Gastric Cancer After Endoscopic Submucosal Dissection by Serum Pepsinogen[NCT02682446] | 800 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| "Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication: Clinical Efficacy Randomized Trial[NCT05664685] | Phase 4 | 204 participants (Anticipated) | Interventional | 2022-10-17 | Recruiting | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial[NCT02635191] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Bismuth Quadruple Therapy in the Second Line and Third Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT03148366] | Phase 3 | 560 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Phase IV Study Comparing the Duration of Sequential Therapy[NCT01042184] | Phase 4 | 900 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes[NCT05449028] | 230 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori:a Prospective, Multicenter, Open Label, Randomized Controlled Study:[NCT05649540] | Phase 4 | 900 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection[NCT00455806] | Phase 3 | 132 participants | Interventional | 2007-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
H pylori eradication was determined by the ^13C-UBT test. (NCT04167670)
Timeframe: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan Dual Therapy | 77.2 |
| Vonoprazan Triple Therapy | 80.8 |
| Lansoprazole Triple Therapy | 68.5 |
H pylori eradication was determined by the ^13C-UBT test. (NCT04167670)
Timeframe: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan Dual Therapy | 69.6 |
| Vonoprazan Triple Therapy | 65.8 |
| Lansoprazole Triple Therapy | 31.9 |
H pylori eradication was determined by the ^13C-UBT test. (NCT04167670)
Timeframe: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan Dual Therapy | 78.5 |
| Vonoprazan Triple Therapy | 84.7 |
| Lansoprazole Triple Therapy | 78.8 |
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
95 reviews available for lansoprazole and Helicobacter Infections
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Topics: Amoxicillin; Anti-Bacterial Agents; Biological Products; Bismuth; Clarithromycin; Drug Therapy, Comb | 2020 |
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gast | 2014 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination | 2016 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Contr | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
[Treatment of NSAID-associated gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
[Reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Esophagitis, Peptic; Gastritis, Atrophic; | 2002 |
[Eradication therapy of Helicobacter pylori for elderly patients in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Interactions; Helicobacter In | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 2002 |
Motion--Helicobacter pylori causes or worsens GERD: arguments against the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
[Helicobacter pylori induced gastritis: recent topics on eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 2002 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2003 |
Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Clarithromycin; Drug The | 2003 |
Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2003 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gas | 2003 |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug The | 2003 |
How can the current strategies for Helicobacter pylori eradication therapy be improved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 2003 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari | 2003 |
Proton pump inhibitors in children: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, P | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
[Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2004 |
Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 2005 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
[Guidelines in the management of H. pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2005 |
[Cap polyposis and Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cla | 2005 |
[Recent topics on important drugs for H. pylori eradication: Lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2005 |
[Triple therapy for eradication of Helicobacter pylori in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Re | 2005 |
[Adverse effects of Helicobacter pylori eradication and its prevention].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2005 |
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Re | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydrox | 2005 |
[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Enzyme | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxy | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents | 2005 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dialysi | 2005 |
[Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydrox | 2005 |
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2006 |
[Helicobacter pylori infection and probiotics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Bifidobacterium; Clarithromycin; Clos | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransf | 2007 |
Dyspepsia in childhood and adolescence: insights and treatment considerations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acetates; Acupuncture Therapy; Adolescent; | 2007 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cells, Cultured; Chemotherapy, Adjuvant; Duodenal | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemotherapy, Adj | 1995 |
The potential value of lansoprazole in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1995 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicoba | 1993 |
[Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Helicobacter Infections; Helicobacter pylori; Humans; Lanso | 1993 |
Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interacti | 1996 |
[Helicobacter pylori eradication: modified triple therapy with lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1996 |
[Diagnosis and treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Dr | 1997 |
Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; C | 1997 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1998 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 1999 |
[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 1999 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1999 |
Proton pump inhibitors and H. pylori infection: why the concern?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastritis, Atrophic; | 1999 |
[Recent guidelines for the management of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2001 |
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
[Progress of tailor-made treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2002 |
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
[The outline of medical treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clari | 2002 |
[Guidelines for the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2002 |
[New triple therapy for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Clinical Trials as Topic; Drug | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2002 |
[Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; | 2002 |
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2002 |
[Adverse effects of H. pylori eradication therapy and its measure].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Diarrhea; Drug Therap | 2002 |
[H. pylori eradication therapy and natural history of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Intractable ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differe | 2002 |
[Peptic ulcer in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Proton pump inhibitors: Efficacy of lansoprazole in eradicating Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Depression, Chemical; Drug The | 2002 |
[Plaunotol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diterpenes; | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpe | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarith | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rh | 2002 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combina | 2002 |
[Practice guidelines for diagnosis and treatment of Helicobacter pylori infections and their application in clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
333 trials available for lansoprazole and Helicobacter Infections
| Article | Year |
|---|---|
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duod | 2022 |
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter I | 2022 |
Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedul | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial.
Topics: Adenomatous Polyps; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitorin | 2020 |
Family History of Gastric Cancer and
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug | 2020 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Co | 2017 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Sc | 2017 |
Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
Topics: Amoxicillin; Clarithromycin; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combina | 2017 |
Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Biopsy; Chronic Disease; Clarith | 2016 |
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Drug Administrat | 2018 |
Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dizziness; Drug Therapy, Combinatio | 2018 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infecti | 2018 |
Intraluminal therapy for Helicobacter pylori infection.
Topics: Acetylcysteine; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration | 2019 |
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradic | 2019 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath | 2013 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2013 |
Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Brazil; Disease Eradication; Double- | 2013 |
Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution.
Topics: Adenocarcinoma, Mucinous; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; beta Catenin; Cell Mem | 2013 |
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2013 |
The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, | 2013 |
A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administr | 2013 |
Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Contraindications; Dru | 2014 |
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Dru | 2014 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2014 |
The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Blood Glucose; Clarithromycin; Drug Therapy, Combination; | 2015 |
A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin | 2014 |
Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Child, Preschool; Clarithromyci | 2014 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2015 |
Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Foll | 2014 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2014 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, | 2015 |
Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Antioxidants; Breath Tests; Child; Clarithromycin; D | 2014 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2015 |
Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, | 2015 |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Topics: Adult; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Admin | 2016 |
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA, Ribosomal; Drug Therapy, Combination; Femal | 2016 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Case-Control Studies; Child; Child, Prescho | 2015 |
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Monitoring; Drug | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the
Topics: Adult; Aged; Breath Tests; Drug Monitoring; Female; Helicobacter Infections; Helicobacter pylori; Hu | 2017 |
Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2008 |
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Clarithromycin; Endoscopy, Gas | 2008 |
Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Be | 2008 |
Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adrenal Cortex Hormones; Adult; Aged; Amoxicillin; Clarithr | 2009 |
Controlled, household-randomized, open-label trial of the effect of treatment of Helicobacter pylori infection on iron deficiency among children in rural Alaska: results at 40 months.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alaska; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Ant | 2009 |
Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: a randomized, double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2008 |
Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2008 |
High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2009 |
Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Dose-Response Relations | 2009 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Clarithromycin; D | 2010 |
Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Double-Blind Meth | 2010 |
Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2010 |
Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl | 2011 |
Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Arginine; Athero | 2010 |
Comparison of two different treatment protocols in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2011 |
Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compoun | 2011 |
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Clarithromyc | 2011 |
Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Ammonia; Anti-Bacterial Agents; Clarithromycin; Drug | 2011 |
A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2011 |
Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2012 |
Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; C | 2012 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2012 |
Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Amoxicillin; Anti-Bacterial Agents; Clar | 2013 |
Eradication of Helicobacter pylori in children in Vietnam in relation to antibiotic resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Chil | 2012 |
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2012 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Drug Resistance; Drug Therapy, Combination; Female; Fluoroquin | 2013 |
Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Endoscopy, G | 2013 |
Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2013 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 2002 |
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Bifidobacterium; Clarithromycin; Combin | 2002 |
Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2002 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; D | 2002 |
The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Ag | 2003 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Nega | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2003 |
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Cro | 2003 |
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug The | 2003 |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2003 |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2003 |
Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-I | 2003 |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2003 |
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Dose-Response Relations | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; B | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotope | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylas | 2003 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2004 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2004 |
Helicobacter pylori eradication: efficacy of conventional therapy in India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Clarithromycin; Double-Blin | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; B | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind | 2004 |
Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Azithromycin; Breath Tests; Child; Doubl | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Re | 2004 |
Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Chronic Disease; | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben | 2004 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis | 2005 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aminopyrine; Breath Tests; Carbon | 2005 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Cl | 2005 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug | 2005 |
Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Drug | 2005 |
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Effect of N-acetyl cysteine on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Anti-Bacterial Agents; Clarithromycin; Drug | 2005 |
[H. pylori eradication package set (Lansap)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Packaging; Drug Therapy, | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug | 2005 |
[Cetraxate hydrochloride (Neuer) induces the effectiveness of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2005 |
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Be | 2006 |
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2006 |
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2006 |
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2006 |
A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alanine; Amoxicillin; Anti- | 2006 |
Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2006 |
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Cisapride; Clari | 2006 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Drug Administ | 2006 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clar | 2006 |
Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteria, | 2007 |
Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2006 |
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydro | 2007 |
Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under | 2007 |
Eradication of Helicobacter pylori in hemodialysis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarb | 2007 |
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Dyspepsia; Femal | 2008 |
Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2007 |
Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Diarrhea; Double- | 2007 |
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2007 |
Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2007 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1995 |
Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Base Sequence; Drug | 1995 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Fa | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Iso | 1995 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Anti | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1995 |
Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Dr | 1995 |
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti- | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1995 |
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Clarithromyc | 1995 |
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinatio | 1995 |
Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1995 |
Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive Syst | 1995 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; | 1993 |
Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithro | 1995 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsu | 1995 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Dru | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1996 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Age | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer | 1996 |
Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer A | 1996 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromyc | 1996 |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clar | 1996 |
High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Dose-Response | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Bli | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1997 |
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Influence of a proton pump inhibitor-based therapy on Helicobacter pylori strain selection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Gastric Muc | 1997 |
Age-dependent eradication of Helicobacter pylori with dual therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Ulc | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1997 |
Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 1996 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Clarithromycin; Drug Therapy | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Ag | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; A | 1998 |
A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Helicobacter Infections; He | 1997 |
Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, | 1998 |
Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool | 1998 |
Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gas | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1998 |
Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Ulcer Agents; Diterpenes; | 1998 |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1998 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Br | 1998 |
Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Azithromycin; Female; Helic | 1998 |
Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Resistance, Microbial; Femal | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1998 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Admini | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1999 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Carnosine; | 1999 |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Chronic Disease; Cros | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Do | 1999 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 1999 |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; C | 1999 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicob | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 1999 |
Evaluation of lansoprazole (an H+/K+-ATPase inhibitor) and azithromycin (an antibiotic) for control of gastric ulceration in swine during periods of feed deprivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animal Feed; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 1999 |
Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Re | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti- | 2000 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2000 |
Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromy | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2000 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Once-daily Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Dose-Response Rel | 2000 |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2000 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biop | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomona | 2000 |
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2000 |
Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; China; Clarithromycin; Drug | 2000 |
Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2000 |
Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2000 |
Helicobacter pylori eradication increases nocturnal acid breakthrough.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Gastric Acid; Helic | 2000 |
[Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; C | 2000 |
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microb | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug | 2000 |
High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Dit | 2000 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
A short-term eradication therapy for Helicobacter pylori acute gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Ant | 2000 |
[Usefulness of new triple therapy containing PPI].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Cl | 2001 |
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2001 |
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
Two weeks triple therapy with lansoprazole, amoxycillin and roxythromycin is better than dual therapy with lansoprazole and amoxycillin for H. pylori infection: a randomised, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Administrat | 2000 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ul | 2001 |
Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; A | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithr | 2001 |
Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 2001 |
Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absenteeism; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Ag | 2000 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti | 2001 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 1999 |
Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azit | 2001 |
Efficacy of a nitroimidazole containing tripletherapy regime in Singapore.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clar | 2001 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2002 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2002 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Cl | 2002 |
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Car | 2002 |
Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Female; Gastric | 2001 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Cla | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
237 other studies available for lansoprazole and Helicobacter Infections
| Article | Year |
|---|---|
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Th | 2022 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing.
Topics: Antigens, Bacterial; Breath Tests; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lans | 2023 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; | 2021 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infec | 2018 |
Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy.
Topics: Adult; Aged; Ambulatory Care Facilities; Cost-Benefit Analysis; Drug Costs; Female; Helicobacter Inf | 2019 |
Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Amoxicillin; Clarithromycin; DNA, Bacterial; Drug Therapy, Combination; Gastritis; Helicobact | 2019 |
Education and imaging. Gastrointestinal: colonic mucosa-associated lymphoid tissue lymphoma regressed by levofloxacin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clar | 2013 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastri | 2013 |
Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Therapy, | 2013 |
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Case-Control Studies; Cla | 2013 |
Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy.
Topics: Adenine; Amoxicillin; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Clarithromycin; | 2014 |
Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.
Topics: Amoxicillin; Child; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Gastritis; Helicobacter Infect | 2014 |
Black tongue due to lansoprazole plus metronidazole.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Drug Therapy, Combination; Female; Helicobacter Inf | 2014 |
[Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
The effect of Helicobacter pylori eradication on the levels of essential trace elements.
Topics: Adult; Aged; Amoxicillin; Copper; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lans | 2014 |
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm.
Topics: Adolescent; Amoxicillin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clarithromycin | 2015 |
Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Brazil; Breath Tests; Drug Admin | 2015 |
Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Ascorbic Acid; Breath Tests; Cla | 2015 |
Eradicating Multi-Drug-Resistant Helicobacter pylori with Four Times Daily Lansoprazole.
Topics: Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter | 2016 |
Does the urea breath test predict eradication of Helicobacter pylori infection?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Radioisotopes; Clarithromycin; Drug | 2016 |
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedul | 2016 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; | 2016 |
Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Breath Tests; Clarithromycin; Female; Gastritis; H | 2016 |
Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Breath Tests; Clarithromycin; Cohort Studies; Fem | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therap | 2016 |
Authors' reply.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; | 2016 |
An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2016 |
Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Body Mass Index; Body We | 2016 |
Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2008 |
Association of laryngopharyngeal manifestations and gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Endoscopy, Digestive System; Esophagitis; Fema | 2009 |
A case of Cronkhite-Canada syndrome: remission after treatment with anti-Helicobacter pylori regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alopecia; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Clarithromycin; Drug | 2009 |
Ten-day sequential therapy of Helicobacter pylori infection in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2010 |
How to manage Helicobacter pylori after sequential therapy failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Cli | 2010 |
Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycyc | 2010 |
The effectiveness of packed therapy with three drugs in Helicobacter pylori eradication in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2010 |
Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Cytochrome P-450 Enzyme System | 2010 |
Age-dependent eradication of Helicobacter pylori in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Amoxici | 2010 |
Long term changes in platelet counts after H. pylori eradication in non-ITP patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2010 |
Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2011 |
CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome | 2011 |
Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; C | 2011 |
Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2011 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarb | 2011 |
Does long-term aspirin use have any effect on Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2011 |
Helicobacter pylori infection-related pancytopenia in a young boy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anemia, Megaloblastic; Anti-Bacter | 2011 |
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Combinations; Fluoroqu | 2011 |
Mass eradication of Helicobacter pylori: feasible and advisable?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2011 |
Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Carcinoma; Cell Transformation, Neoplastic; Chromo | 2011 |
Role of gastritis pattern on Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2012 |
Lansoprazole induces collagenous colitis in the colon of Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Colitis, Collagenous; Colon; Gastric Mucosa; Gerbi | 2011 |
Comparison of sequential and standard therapy for Helicobacter pylori eradication in children and investigation of clarithromycin resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Aryl H | 2012 |
[Effect of pharmaceutical care in the diagnosis of Helicobacter pylori infection using 13C-urea breath test].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2012 |
[Eradication of helicobacter pylori: symptomatic treatment of reflux disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Ther | 2002 |
Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial | 2002 |
Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
One week regimen of esomeprazole based triple therapy is sufficient for duodenal ulcer healing and Helicobacter pylori eradication in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2002 |
Functional dyspepsia: bye-bye to PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; China; Dyspepsia; Gastroesophageal R | 2002 |
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocol | 2002 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
Utility and limitations of a method for detecting Helicobacter pylori-specific antigens in the stool.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antigens, Bact | 2003 |
Isolated granulomatous gastritis successfully treated by Helicobacter pylori eradication: a possible association between granulomatous gastritis and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2003 |
Gastric myoelectrical activity in patients with recurrent gastric or duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Digest | 2003 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacte | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 2003 |
Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Blood Platelets; Drug Therapy, Combi | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Anti-Bacterial Agents; A | 2004 |
Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Female; Fibroblast Growth Factor | 2004 |
[Successful treatment of long-standing iron-deficiency anemia in adults by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Clarithr | 2004 |
Complete remission of cyclic thrombocytopenia after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; D | 2004 |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Colony Count, Mic | 2004 |
Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Enzyme Inhibitors; Esomeprazole; Esophagitis; | 2004 |
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cyclooxygenase 2; Female; Follow-Up Studies; G | 2004 |
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cohort Studies; | 2004 |
Effect of lansoprazole for an idiopathic thrombocytopenic purpura patient with Helicobacter pylori infection who did not respond to prednisolone treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Helicobacter Infections; Helic | 2004 |
Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, | 2004 |
Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Apoptosis; Cel | 2004 |
Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2004 |
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug | 2004 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2005 |
The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Breath Tests; Carbon Isotopes; Enzyme Inhibitors; Fem | 2005 |
Influence of antimicrobial treatment for Helicobacter pylori infection on the intestinal microflora in Japanese macaques.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Infective Agents; Bacteria, Aero | 2005 |
Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Th | 2005 |
Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2005 |
[Distribution of Helicobacter pylori in stomach before and after the administration of Lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Mucosa; Gastriti | 2005 |
Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2005 |
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithrom | 2005 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Gast | 2005 |
Determinants of non-response in Helicobacter pylori eradication trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
[The cause of failure of eradication treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acidity Determination; Ga | 2005 |
Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Anti-Bacterial Agents; Clarithromycin; Drug | 2005 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
[Pseudomembranous colitis after Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2006 |
Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Helic | 2006 |
Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2007 |
Contrast-enhanced ultrasonographic assessment of the response of Ménétrier disease to Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Contrast Media; Diagnosis, Dif | 2006 |
The Efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura--the first study in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin | 2006 |
Some fibrocystic breast change may be caused by sexually transmitted H. pylori during oral nipple contact: supporting literature and case report of resolution after gut H. pylori eradication treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Female; Fibrocyst | 2007 |
Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Ag | 2006 |
Key points in the management of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esophageal | 2007 |
Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2007 |
Influence of H pylori on plasma ghrelin in patients without atrophic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective | 2007 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2007 |
Pyroderma gangrenosum: resolution after treatment for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2006 |
Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agent | 2008 |
Effect of Helicobacter pylori eradication on gastric carcinogenesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Amoxicillin; Animals; Animals, Outbred Stra | 2008 |
The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents | 2008 |
Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective | 2008 |
Evaluation of antibiotic therapy for eradication of "Candidatus Helicobacter heilmannii".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Drug Therapy, | 2008 |
Reflux masquerader: acute Helicobacter pylori infection in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Bacterial Agents; Clarithr | 2008 |
Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Helicobacter | 1995 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy | 1995 |
Proceedings of the 2nd International Colloquium on Proton Pump Inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Enzyme I | 1995 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Helicobacter Infections; He | 1993 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhi | 1995 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1995 |
Validity of various diagnostic tests to evaluate cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Bacteriological Techniq | 1996 |
Helicobacter pylori and lanzoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Helicobacter | 1996 |
Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 1996 |
Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1996 |
Re: short-term treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1996 |
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blot | 1996 |
Atopic dermatitis successfully treated by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Blott | 1996 |
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1996 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; | 1997 |
Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Comb | 1997 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1996 |
[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Co | 1997 |
[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin | 1997 |
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastric Mucosa; Gastrins; Gastritis; H | 1997 |
Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Car | 1997 |
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 1997 |
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1997 |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 1997 |
Pharmacological therapy of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Ag | 1997 |
[Two step therapy for education of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 1997 |
H. pylori eradication by LAC.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1997 |
Lansoprazole, H. pylori, and atrophic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastritis, Atrophic; Helicobacter Infect | 1997 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Tr | 1996 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resist | 1996 |
[Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Ba | 1997 |
Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 1997 |
Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony | 1997 |
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Epithelial C | 1997 |
[Gastric lymphoma--a case report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Gastrosc | 1998 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administ | 1998 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Dru | 1998 |
[Problems in the diagnosis and treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter py | 1996 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studi | 1998 |
[Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Child; Drug Resistance, Microbial; Drug Therap | 1998 |
Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chem | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl | 1998 |
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Diagnostic Errors; False N | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bism | 1998 |
[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti- | 1998 |
Healing of cimetidine-resistant Ménétrier's disease by eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; | 1998 |
Combined activity of azithromycin and lansoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Drug Synergism; Helico | 1999 |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, | 1999 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tes | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; A | 1999 |
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2000 |
Continued use of the proton-pump inhibitor lansoprazole following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Female; Helicobacter Infections; Helicob | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therap | 2000 |
[Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female | 2000 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cel | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2000 |
Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antibiosis; Bacterial Adhesion; Butyric Acid; Clos | 2000 |
Iron-deficiency anemia associated with Helicobacter pylori gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anemia, Iron-Deficiency; Anti-Bacterial Agents; | 2000 |
Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2000 |
Treatment of Helicobacter pylori infection: is less more?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 2000 |
Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Helicobacter pylori infection in renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug | 2000 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; D | 2001 |
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Drug Therapy, | 2001 |
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2001 |
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Biological Transpo | 2001 |
Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Breath Tests; False Negative Reactions; Female; Gastric Aci | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Ampulla of Vater; Biopsy; Clarithromycin; Comm | 2001 |
Lansoprazole triple therapy for Turkish children with Helicobacter pylori infections.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Female; Helicobacter | 2001 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2001 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease | 2001 |
Resolution of Ménétrier's disease after Helicobacter pylori eradicating therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2001 |
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Br | 2001 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
Key topics in Helicobacter pylori eradication in the management of the dyspeptic patient: a panel discussion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Heli | 2001 |
Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infecti | 2001 |
Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Helicobacter Infections; Helicobacter pylori; | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2002 |
[Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2001 |
Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2002 |
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Combinations | 2002 |
[Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents | 2002 |
Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
[Gastroduodenal ulcer in childhood].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Inflammatory Agents, Non-Ster | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2002 |